



## Clinical trial results:

### Phase 1/2 Study of Intratumoral G100 with or without Pembrolizumab or Rituximab in Patients with Follicular Non-Hodgkin's Lymphoma

#### Summary

|                          |                |
|--------------------------|----------------|
| EudraCT number           | 2015-005382-23 |
| Trial protocol           | GB ES FR       |
| Global end of trial date | 01 August 2019 |

#### Results information

|                                |                |
|--------------------------------|----------------|
| Result version number          | v1 (current)   |
| This version publication date  | 12 August 2020 |
| First version publication date | 12 August 2020 |

#### Trial information

##### Trial identification

|                       |                         |
|-----------------------|-------------------------|
| Sponsor protocol code | MK-3475-174 (IMDZ-G142) |
|-----------------------|-------------------------|

##### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT02501473 |
| WHO universal trial number (UTN)   | -           |

Notes:

#### Sponsors

|                              |                                                                                              |
|------------------------------|----------------------------------------------------------------------------------------------|
| Sponsor organisation name    | Merck Sharp & Dohme Corp.                                                                    |
| Sponsor organisation address | 2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033                               |
| Public contact               | Clinical Trials Disclosure, Merck Sharp & Dohme Corp.,<br>ClinicalTrialsDisclosure@merck.com |
| Scientific contact           | Clinical Trials Disclosure, Merck Sharp & Dohme Corp.,<br>ClinicalTrialsDisclosure@merck.com |

Notes:

#### Paediatric regulatory details

|                                                                      |    |
|----------------------------------------------------------------------|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

---

**Results analysis stage**

---

|                                                      |                |
|------------------------------------------------------|----------------|
| Analysis stage                                       | Final          |
| Date of interim/final analysis                       | 01 August 2019 |
| Is this the analysis of the primary completion data? | Yes            |
| Primary completion date                              | 01 August 2019 |
| Global end of trial reached?                         | Yes            |
| Global end of trial date                             | 01 August 2019 |
| Was the trial ended prematurely?                     | Yes            |

Notes:

---

**General information about the trial**

---

Main objective of the trial:

This is a Phase 1/2 open label trial of G100 in participants with low grade Non-Hodgkin's Lymphoma (NHL). G100 is composed of glucopranosyl lipid A in a stable emulsion and is a potent TLR4 (toll-like receptor-4) agonist. G100 will be administered by direct injection (intratumorally) into tumors of low grade NHL with or without standard low dose radiation therapy. Preclinical models and clinical studies in other cancers such as Merkel cell carcinoma have demonstrated that G100 administered in this manner can alter the tumor microenvironment, activate dendritic cells, T cells and other immune cells and induce systemic anti-tumor immune responses. In this trial, the safety, immunogenicity, and preliminary clinical efficacy of G100 will be examined alone or with pembrolizumab.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

|                                                           |                  |
|-----------------------------------------------------------|------------------|
| Actual start date of recruitment                          | 03 February 2016 |
| Long term follow-up planned                               | Yes              |
| Long term follow-up rationale                             | Safety, Efficacy |
| Long term follow-up duration                              | 16 Months        |
| Independent data monitoring committee (IDMC) involvement? | Yes              |

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

|                                      |                   |
|--------------------------------------|-------------------|
| Country: Number of subjects enrolled | United States: 41 |
| Country: Number of subjects enrolled | United Kingdom: 2 |
| Country: Number of subjects enrolled | France: 1         |
| Country: Number of subjects enrolled | Spain: 8          |
| Worldwide total number of subjects   | 52                |
| EEA total number of subjects         | 11                |

Notes:

---

**Subjects enrolled per age group**

---

|                                           |   |
|-------------------------------------------|---|
| In utero                                  | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |

|                                          |    |
|------------------------------------------|----|
| Newborns (0-27 days)                     | 0  |
| Infants and toddlers (28 days-23 months) | 0  |
| Children (2-11 years)                    | 0  |
| Adolescents (12-17 years)                | 0  |
| Adults (18-64 years)                     | 31 |
| From 65 to 84 years                      | 21 |
| 85 years and over                        | 0  |

## Subject disposition

### Recruitment

Recruitment details:

Participants were enrolled in the study at clinical sites in the United States and Europe.

### Pre-assignment

Screening details:

Part 5, G100 plus Rituximab, Dose Escalation: 12 to 24 participants were planned; no participant was enrolled or dosed.

### Period 1

|                              |                                |
|------------------------------|--------------------------------|
| Period 1 title               | Overall Study (overall period) |
| Is this the baseline period? | Yes                            |
| Allocation method            | Randomised - controlled        |
| Blinding used                | Not blinded                    |

### Arms

|                              |                                           |
|------------------------------|-------------------------------------------|
| Are arms mutually exclusive? | Yes                                       |
| <b>Arm title</b>             | Part 1: Local Radiation + G100 5µg/lesion |

Arm description:

Part 1: Local radiation and G100 [glucopyranosyl lipid A stable emulsion, GLA-SE] at 5µg/lesion administered intratumoral (IT) into accessible lesions for up to 8 weeks.

|                                        |                  |
|----------------------------------------|------------------|
| Arm type                               | Experimental     |
| Investigational medicinal product name | G100             |
| Investigational medicinal product code |                  |
| Other name                             |                  |
| Pharmaceutical forms                   | Injection        |
| Routes of administration               | Intratumoral use |

Dosage and administration details:

G100 [glucopyranosyl lipid A stable emulsion, GLA-SE] at 5µg/lesion administered intratumoral (IT) into accessible lesions for up to 8 weeks.

|                                        |                        |
|----------------------------------------|------------------------|
| Investigational medicinal product name | Local radiation        |
| Investigational medicinal product code |                        |
| Other name                             |                        |
| Pharmaceutical forms                   | Radionuclide generator |
| Routes of administration               | Local use              |

Dosage and administration details:

Radiation of a tumor in the radiation field on Day 1.

|                  |                                            |
|------------------|--------------------------------------------|
| <b>Arm title</b> | Part 1: Local Radiation + G100 10µg/lesion |
|------------------|--------------------------------------------|

Arm description:

Part 1: Local radiation and G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.

|                                        |                        |
|----------------------------------------|------------------------|
| Arm type                               | Experimental           |
| Investigational medicinal product name | Local radiation        |
| Investigational medicinal product code |                        |
| Other name                             |                        |
| Pharmaceutical forms                   | Radionuclide generator |
| Routes of administration               | Local use              |

Dosage and administration details:

Radiation of a tumor in the radiation field on Day 1.

|                                                                                                                                                                                                         |                                                                |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|
| Investigational medicinal product name                                                                                                                                                                  | G100                                                           |
| Investigational medicinal product code                                                                                                                                                                  |                                                                |
| Other name                                                                                                                                                                                              |                                                                |
| Pharmaceutical forms                                                                                                                                                                                    | Injection                                                      |
| Routes of administration                                                                                                                                                                                | Intratumoral use                                               |
| Dosage and administration details:                                                                                                                                                                      |                                                                |
| G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.                                                                                                                          |                                                                |
| <b>Arm title</b>                                                                                                                                                                                        | Part 2: Local Radiation + G100 10µg/lesion                     |
| Arm description:                                                                                                                                                                                        |                                                                |
| Part 2: Local radiation and G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.                                                                                              |                                                                |
| Arm type                                                                                                                                                                                                | Experimental                                                   |
| Investigational medicinal product name                                                                                                                                                                  | Local radiation                                                |
| Investigational medicinal product code                                                                                                                                                                  |                                                                |
| Other name                                                                                                                                                                                              |                                                                |
| Pharmaceutical forms                                                                                                                                                                                    | Radionuclide generator                                         |
| Routes of administration                                                                                                                                                                                | Local use                                                      |
| Dosage and administration details:                                                                                                                                                                      |                                                                |
| Radiation of a tumor in the radiation field on Day 1.                                                                                                                                                   |                                                                |
| Investigational medicinal product name                                                                                                                                                                  | G100                                                           |
| Investigational medicinal product code                                                                                                                                                                  |                                                                |
| Other name                                                                                                                                                                                              |                                                                |
| Pharmaceutical forms                                                                                                                                                                                    | Injection                                                      |
| Routes of administration                                                                                                                                                                                | Intratumoral use                                               |
| Dosage and administration details:                                                                                                                                                                      |                                                                |
| G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.                                                                                                                          |                                                                |
| <b>Arm title</b>                                                                                                                                                                                        | Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg |
| Arm description:                                                                                                                                                                                        |                                                                |
| Part 2: Local radiation and G100 at 10µg/lesion administered IT into accessible tumors for up to 8 weeks; pembrolizumab 200mg intravenously (IV) administered every 3 weeks (Q3W) IV for up to 2 years. |                                                                |
| Arm type                                                                                                                                                                                                | Experimental                                                   |
| Investigational medicinal product name                                                                                                                                                                  | G100                                                           |
| Investigational medicinal product code                                                                                                                                                                  |                                                                |
| Other name                                                                                                                                                                                              |                                                                |
| Pharmaceutical forms                                                                                                                                                                                    | Injection                                                      |
| Routes of administration                                                                                                                                                                                | Intratumoral use                                               |
| Dosage and administration details:                                                                                                                                                                      |                                                                |
| G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.                                                                                                                          |                                                                |
| Investigational medicinal product name                                                                                                                                                                  | Pembrolizumab                                                  |
| Investigational medicinal product code                                                                                                                                                                  |                                                                |
| Other name                                                                                                                                                                                              |                                                                |
| Pharmaceutical forms                                                                                                                                                                                    | Solution for infusion                                          |
| Routes of administration                                                                                                                                                                                | Intravenous use                                                |
| Dosage and administration details:                                                                                                                                                                      |                                                                |
| Pembrolizumab 200mg intravenously (IV) administered every 3 weeks (Q3W) IV for up to 2 years.                                                                                                           |                                                                |
| Investigational medicinal product name                                                                                                                                                                  | Local radiation                                                |
| Investigational medicinal product code                                                                                                                                                                  |                                                                |
| Other name                                                                                                                                                                                              |                                                                |
| Pharmaceutical forms                                                                                                                                                                                    | Radionuclide generator                                         |
| Routes of administration                                                                                                                                                                                | Local use                                                      |

Dosage and administration details:

Radiation of a tumor in the radiation field on Day 1.

|                                                                                                                                                                                         |                                                           |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|
| <b>Arm title</b>                                                                                                                                                                        | Part 2: Local Radiation, G100 20µg/lesion in Large Tumors |
| Arm description:<br>Part 2: Local radiation and G100 at 20µg/lesion administered IT into accessible large tumors (injectable lymphoma mass(es) ≥ 4 cm in total size) for up to 8 weeks. |                                                           |
| Arm type                                                                                                                                                                                | Experimental                                              |
| Investigational medicinal product name                                                                                                                                                  | Local radiation                                           |
| Investigational medicinal product code                                                                                                                                                  |                                                           |
| Other name                                                                                                                                                                              |                                                           |
| Pharmaceutical forms                                                                                                                                                                    | Radionuclide generator                                    |
| Routes of administration                                                                                                                                                                | Local use                                                 |

Dosage and administration details:

Radiation of a tumor in the radiation field on Day 1.

|                                        |                  |
|----------------------------------------|------------------|
| Investigational medicinal product name | G100             |
| Investigational medicinal product code |                  |
| Other name                             |                  |
| Pharmaceutical forms                   | Injection        |
| Routes of administration               | Intratumoral use |

Dosage and administration details:

G100 at 20 µg/lesion administered IT into accessible large tumors (injectable lymphoma mass(es) ≥ 4 cm in total size) for up to 8 weeks.

|                                                                                                                                |                                            |
|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|
| <b>Arm title</b>                                                                                                               | Part 3: Local Radiation + G100 20µg/lesion |
| Arm description:<br>Part 3: Local radiation and G100 at 20µg/lesion administered IT into accessible lesions for up to 8 weeks. |                                            |
| Arm type                                                                                                                       | Experimental                               |
| Investigational medicinal product name                                                                                         | G100                                       |
| Investigational medicinal product code                                                                                         |                                            |
| Other name                                                                                                                     |                                            |
| Pharmaceutical forms                                                                                                           | Injection                                  |
| Routes of administration                                                                                                       | Intratumoral use                           |

Dosage and administration details:

G100 at 20µg/lesion administered IT into accessible lesions for up to 8 weeks.

|                                        |                        |
|----------------------------------------|------------------------|
| Investigational medicinal product name | Local radiation        |
| Investigational medicinal product code |                        |
| Other name                             |                        |
| Pharmaceutical forms                   | Radionuclide generator |
| Routes of administration               | Local use              |

Dosage and administration details:

Radiation of a tumor in the radiation field on Day 1.

|                                                                                                                                                                              |                                                  |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|
| <b>Arm title</b>                                                                                                                                                             | Part 4: G100 20µg/lesion and Pembrolizumab 200mg |
| Arm description:<br>Part 4: G100 at 20µg/lesion administered IT into accessible lesions for up to 8 weeks and Pembrolizumab 200mg IV and administered Q3W for up to 2 years. |                                                  |
| Arm type                                                                                                                                                                     | Experimental                                     |

|                                        |                       |
|----------------------------------------|-----------------------|
| Investigational medicinal product name | Pembrolizumab         |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

Dosage and administration details:

Pembrolizumab 200mg intravenously (IV) administered every 3 weeks (Q3W) IV for up to 2 years.

|                                        |                  |
|----------------------------------------|------------------|
| Investigational medicinal product name | G100             |
| Investigational medicinal product code |                  |
| Other name                             |                  |
| Pharmaceutical forms                   | Injection        |
| Routes of administration               | Intratumoral use |

Dosage and administration details:

G100 at 20µg/lesion administered IT into accessible lesions for up to 8 weeks.

| <b>Number of subjects in period 1</b> | Part 1: Local Radiation + G100 5µg/lesion | Part 1: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion |
|---------------------------------------|-------------------------------------------|--------------------------------------------|--------------------------------------------|
| Started                               | 3                                         | 3                                          | 13                                         |
| Treated                               | 3                                         | 3                                          | 13                                         |
| Completed                             | 0                                         | 0                                          | 0                                          |
| Not completed                         | 3                                         | 3                                          | 13                                         |
| Adverse event, serious fatal          | -                                         | -                                          | 1                                          |
| Consent withdrawn by subject          | -                                         | -                                          | 3                                          |
| Study Terminated                      | 2                                         | 3                                          | 7                                          |
| Lost to follow-up                     | 1                                         | -                                          | 1                                          |
| Reason not specified                  | -                                         | -                                          | 1                                          |

| <b>Number of subjects in period 1</b> | Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg | Part 2: Local Radiation, G100 20µg/lesion in Large Tumors | Part 3: Local Radiation + G100 20µg/lesion |
|---------------------------------------|----------------------------------------------------------------|-----------------------------------------------------------|--------------------------------------------|
| Started                               | 14                                                             | 4                                                         | 14                                         |
| Treated                               | 13                                                             | 4                                                         | 14                                         |
| Completed                             | 0                                                              | 0                                                         | 0                                          |
| Not completed                         | 14                                                             | 4                                                         | 14                                         |
| Adverse event, serious fatal          | 1                                                              | -                                                         | 1                                          |
| Consent withdrawn by subject          | 3                                                              | 2                                                         | 2                                          |
| Study Terminated                      | 9                                                              | 2                                                         | 10                                         |
| Lost to follow-up                     | -                                                              | -                                                         | 1                                          |
| Reason not specified                  | 1                                                              | -                                                         | -                                          |

| <b>Number of subjects in period 1</b> | Part 4: G100 20µg/lesion and Pembrolizumab 200mg |
|---------------------------------------|--------------------------------------------------|
| Started                               | 1                                                |

|                              |   |
|------------------------------|---|
| Treated                      | 1 |
| Completed                    | 0 |
| Not completed                | 1 |
| Adverse event, serious fatal | - |
| Consent withdrawn by subject | - |
| Study Terminated             | 1 |
| Lost to follow-up            | - |
| Reason not specified         | - |

## Baseline characteristics

### Reporting groups

|                                                                                                                                                                                                                                         |                                                                |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|
| Reporting group title                                                                                                                                                                                                                   | Part 1: Local Radiation + G100 5µg/lesion                      |
| Reporting group description:<br>Part 1: Local radiation and G100 [glucopyranosyl lipid A stable emulsion, GLA-SE] at 5µg/lesion administered intratumoral (IT) into accessible lesions for up to 8 weeks.                               |                                                                |
| Reporting group title                                                                                                                                                                                                                   | Part 1: Local Radiation + G100 10µg/lesion                     |
| Reporting group description:<br>Part 1: Local radiation and G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.                                                                                              |                                                                |
| Reporting group title                                                                                                                                                                                                                   | Part 2: Local Radiation + G100 10µg/lesion                     |
| Reporting group description:<br>Part 2: Local radiation and G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.                                                                                              |                                                                |
| Reporting group title                                                                                                                                                                                                                   | Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg |
| Reporting group description:<br>Part 2: Local radiation and G100 at 10µg/lesion administered IT into accessible tumors for up to 8 weeks; pembrolizumab 200mg intravenously (IV) administered every 3 weeks (Q3W) IV for up to 2 years. |                                                                |
| Reporting group title                                                                                                                                                                                                                   | Part 2: Local Radiation, G100 20µg/lesion in Large Tumors      |
| Reporting group description:<br>Part 2: Local radiation and G100 at 20µg/lesion administered IT into accessible large tumors (injectable lymphoma mass(es) ≥ 4 cm in total size) for up to 8 weeks.                                     |                                                                |
| Reporting group title                                                                                                                                                                                                                   | Part 3: Local Radiation + G100 20µg/lesion                     |
| Reporting group description:<br>Part 3: Local radiation and G100 at 20µg/lesion administered IT into accessible lesions for up to 8 weeks.                                                                                              |                                                                |
| Reporting group title                                                                                                                                                                                                                   | Part 4: G100 20µg/lesion and Pembrolizumab 200mg               |
| Reporting group description:<br>Part 4: G100 at 20µg/lesion administered IT into accessible lesions for up to 8 weeks and Pembrolizumab 200mg IV and administered Q3W for up to 2 years.                                                |                                                                |

| Reporting group values                             | Part 1: Local Radiation + G100 5µg/lesion | Part 1: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion |
|----------------------------------------------------|-------------------------------------------|--------------------------------------------|--------------------------------------------|
| Number of subjects                                 | 3                                         | 3                                          | 13                                         |
| Age categorical                                    |                                           |                                            |                                            |
| There was no enrollment in Part 5.                 |                                           |                                            |                                            |
| Units: Subjects                                    |                                           |                                            |                                            |
| In utero                                           | 0                                         | 0                                          | 0                                          |
| Preterm newborn infants (gestational age < 37 wks) | 0                                         | 0                                          | 0                                          |
| Newborns (0-27 days)                               | 0                                         | 0                                          | 0                                          |
| Infants and toddlers (28 days-23 months)           | 0                                         | 0                                          | 0                                          |
| Children (2-11 years)                              | 0                                         | 0                                          | 0                                          |
| Adolescents (12-17 years)                          | 0                                         | 0                                          | 0                                          |
| Adults (18-64 years)                               | 2                                         | 2                                          | 6                                          |
| From 65-84 years                                   | 1                                         | 1                                          | 7                                          |
| 85 years and over                                  | 0                                         | 0                                          | 0                                          |

|                                                                                                                                    |         |         |         |
|------------------------------------------------------------------------------------------------------------------------------------|---------|---------|---------|
| Age Continuous                                                                                                                     |         |         |         |
| Age not reported for the participant in Part 4 due to risk of identification of a person. No participants were enrolled in Part 5. |         |         |         |
| Units: years                                                                                                                       |         |         |         |
| arithmetic mean                                                                                                                    | 54.0    | 56.3    | 60.2    |
| standard deviation                                                                                                                 | ± 13.45 | ± 16.07 | ± 10.26 |
| Sex: Female, Male                                                                                                                  |         |         |         |
| No participants enrolled in Part 5.                                                                                                |         |         |         |
| Units: Participants                                                                                                                |         |         |         |
| Female                                                                                                                             | 1       | 2       | 3       |
| Male                                                                                                                               | 2       | 1       | 10      |
| Race (NIH/OMB)                                                                                                                     |         |         |         |
| No participants enrolled in Part 5.                                                                                                |         |         |         |
| Units: Subjects                                                                                                                    |         |         |         |
| American Indian or Alaska Native                                                                                                   | 0       | 0       | 0       |
| Asian                                                                                                                              | 0       | 0       | 0       |
| Native Hawaiian or Other Pacific Islander                                                                                          | 0       | 0       | 0       |
| Black or African American                                                                                                          | 0       | 0       | 1       |
| White                                                                                                                              | 2       | 3       | 11      |
| More than one race                                                                                                                 | 0       | 0       | 0       |
| Unknown or Not Reported                                                                                                            | 1       | 0       | 1       |
| Ethnicity (NIH/OMB)                                                                                                                |         |         |         |
| No participants enrolled in Part 5.                                                                                                |         |         |         |
| Units: Subjects                                                                                                                    |         |         |         |
| Hispanic or Latino                                                                                                                 | 0       | 1       | 1       |
| Not Hispanic or Latino                                                                                                             | 2       | 2       | 12      |
| Unknown or Not Reported                                                                                                            | 1       | 0       | 0       |

| <b>Reporting group values</b>                                                                                                      | Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg | Part 2: Local Radiation, G100 20µg/lesion in Large Tumors | Part 3: Local Radiation + G100 20µg/lesion |
|------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|-----------------------------------------------------------|--------------------------------------------|
| Number of subjects                                                                                                                 | 14                                                             | 4                                                         | 14                                         |
| Age categorical                                                                                                                    |                                                                |                                                           |                                            |
| There was no enrollment in Part 5.                                                                                                 |                                                                |                                                           |                                            |
| Units: Subjects                                                                                                                    |                                                                |                                                           |                                            |
| In utero                                                                                                                           | 0                                                              | 0                                                         | 0                                          |
| Preterm newborn infants (gestational age < 37 wks)                                                                                 | 0                                                              | 0                                                         | 0                                          |
| Newborns (0-27 days)                                                                                                               | 0                                                              | 0                                                         | 0                                          |
| Infants and toddlers (28 days-23 months)                                                                                           | 0                                                              | 0                                                         | 0                                          |
| Children (2-11 years)                                                                                                              | 0                                                              | 0                                                         | 0                                          |
| Adolescents (12-17 years)                                                                                                          | 0                                                              | 0                                                         | 0                                          |
| Adults (18-64 years)                                                                                                               | 10                                                             | 3                                                         | 8                                          |
| From 65-84 years                                                                                                                   | 4                                                              | 1                                                         | 6                                          |
| 85 years and over                                                                                                                  | 0                                                              | 0                                                         | 0                                          |
| Age Continuous                                                                                                                     |                                                                |                                                           |                                            |
| Age not reported for the participant in Part 4 due to risk of identification of a person. No participants were enrolled in Part 5. |                                                                |                                                           |                                            |
| Units: years                                                                                                                       |                                                                |                                                           |                                            |
| arithmetic mean                                                                                                                    | 57.6                                                           | 59.3                                                      | 63.9                                       |
| standard deviation                                                                                                                 | ± 10.98                                                        | ± 5.85                                                    | ± 8.74                                     |

|                                           |    |   |    |
|-------------------------------------------|----|---|----|
| Sex: Female, Male                         |    |   |    |
| No participants enrolled in Part 5.       |    |   |    |
| Units: Participants                       |    |   |    |
| Female                                    | 3  | 1 | 5  |
| Male                                      | 11 | 3 | 9  |
| Race (NIH/OMB)                            |    |   |    |
| No participants enrolled in Part 5.       |    |   |    |
| Units: Subjects                           |    |   |    |
| American Indian or Alaska Native          | 0  | 0 | 0  |
| Asian                                     | 0  | 1 | 0  |
| Native Hawaiian or Other Pacific Islander | 0  | 0 | 0  |
| Black or African American                 | 0  | 0 | 1  |
| White                                     | 13 | 2 | 12 |
| More than one race                        | 0  | 0 | 0  |
| Unknown or Not Reported                   | 1  | 1 | 1  |
| Ethnicity (NIH/OMB)                       |    |   |    |
| No participants enrolled in Part 5.       |    |   |    |
| Units: Subjects                           |    |   |    |
| Hispanic or Latino                        | 3  | 0 | 0  |
| Not Hispanic or Latino                    | 11 | 4 | 13 |
| Unknown or Not Reported                   | 0  | 0 | 1  |

| Reporting group values                                                                                                             | Part 4: G100<br>20µg/lesion and<br>Pembrolizumab<br>200mg | Total |  |
|------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|-------|--|
| Number of subjects                                                                                                                 | 1                                                         | 52    |  |
| Age categorical                                                                                                                    |                                                           |       |  |
| There was no enrollment in Part 5.                                                                                                 |                                                           |       |  |
| Units: Subjects                                                                                                                    |                                                           |       |  |
| In utero                                                                                                                           | 0                                                         | 0     |  |
| Preterm newborn infants<br>(gestational age < 37 wks)                                                                              | 0                                                         | 0     |  |
| Newborns (0-27 days)                                                                                                               | 0                                                         | 0     |  |
| Infants and toddlers (28 days-23 months)                                                                                           | 0                                                         | 0     |  |
| Children (2-11 years)                                                                                                              | 0                                                         | 0     |  |
| Adolescents (12-17 years)                                                                                                          | 0                                                         | 0     |  |
| Adults (18-64 years)                                                                                                               | 0                                                         | 31    |  |
| From 65-84 years                                                                                                                   | 1                                                         | 21    |  |
| 85 years and over                                                                                                                  | 0                                                         | 0     |  |
| Age Continuous                                                                                                                     |                                                           |       |  |
| Age not reported for the participant in Part 4 due to risk of identification of a person. No participants were enrolled in Part 5. |                                                           |       |  |
| Units: years                                                                                                                       |                                                           |       |  |
| arithmetic mean                                                                                                                    | 0                                                         |       |  |
| standard deviation                                                                                                                 | ± 0                                                       | -     |  |
| Sex: Female, Male                                                                                                                  |                                                           |       |  |
| No participants enrolled in Part 5.                                                                                                |                                                           |       |  |
| Units: Participants                                                                                                                |                                                           |       |  |
| Female                                                                                                                             | 1                                                         | 16    |  |
| Male                                                                                                                               | 0                                                         | 36    |  |

|                                           |   |    |  |
|-------------------------------------------|---|----|--|
| Race (NIH/OMB)                            |   |    |  |
| No participants enrolled in Part 5.       |   |    |  |
| Units: Subjects                           |   |    |  |
| American Indian or Alaska Native          | 0 | 0  |  |
| Asian                                     | 0 | 1  |  |
| Native Hawaiian or Other Pacific Islander | 0 | 0  |  |
| Black or African American                 | 0 | 2  |  |
| White                                     | 1 | 44 |  |
| More than one race                        | 0 | 0  |  |
| Unknown or Not Reported                   | 0 | 5  |  |
| Ethnicity (NIH/OMB)                       |   |    |  |
| No participants enrolled in Part 5.       |   |    |  |
| Units: Subjects                           |   |    |  |
| Hispanic or Latino                        | 0 | 5  |  |
| Not Hispanic or Latino                    | 1 | 45 |  |
| Unknown or Not Reported                   | 0 | 2  |  |

## End points

### End points reporting groups

|                                                                                                                                                                                                                                         |                                                                |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|
| Reporting group title                                                                                                                                                                                                                   | Part 1: Local Radiation + G100 5µg/lesion                      |
| Reporting group description:<br>Part 1: Local radiation and G100 [glucopyranosyl lipid A stable emulsion, GLA-SE] at 5µg/lesion administered intratumoral (IT) into accessible lesions for up to 8 weeks.                               |                                                                |
| Reporting group title                                                                                                                                                                                                                   | Part 1: Local Radiation + G100 10µg/lesion                     |
| Reporting group description:<br>Part 1: Local radiation and G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.                                                                                              |                                                                |
| Reporting group title                                                                                                                                                                                                                   | Part 2: Local Radiation + G100 10µg/lesion                     |
| Reporting group description:<br>Part 2: Local radiation and G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.                                                                                              |                                                                |
| Reporting group title                                                                                                                                                                                                                   | Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg |
| Reporting group description:<br>Part 2: Local radiation and G100 at 10µg/lesion administered IT into accessible tumors for up to 8 weeks; pembrolizumab 200mg intravenously (IV) administered every 3 weeks (Q3W) IV for up to 2 years. |                                                                |
| Reporting group title                                                                                                                                                                                                                   | Part 2: Local Radiation, G100 20µg/lesion in Large Tumors      |
| Reporting group description:<br>Part 2: Local radiation and G100 at 20µg/lesion administered IT into accessible large tumors (injectable lymphoma mass(es) $\geq$ 4 cm in total size) for up to 8 weeks.                                |                                                                |
| Reporting group title                                                                                                                                                                                                                   | Part 3: Local Radiation + G100 20µg/lesion                     |
| Reporting group description:<br>Part 3: Local radiation and G100 at 20µg/lesion administered IT into accessible lesions for up to 8 weeks.                                                                                              |                                                                |
| Reporting group title                                                                                                                                                                                                                   | Part 4: G100 20µg/lesion and Pembrolizumab 200mg               |
| Reporting group description:<br>Part 4: G100 at 20µg/lesion administered IT into accessible lesions for up to 8 weeks and Pembrolizumab 200mg IV and administered Q3W for up to 2 years.                                                |                                                                |

### Primary: Number of Participants with an Adverse Event (AE)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Number of Participants with an Adverse Event (AE) <sup>[1]</sup> |
| End point description:<br>An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The analysis population included all enrolled participants who received at least 1 injection of G100 after standard local radiation. |                                                                  |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Primary                                                          |
| End point timeframe:<br>Up to approximately 42 months                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                  |

#### Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned or performed for this endpoint.

| End point values            | Part 1: Local Radiation + G100 5µg/lesion | Part 1: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion+P embrolizumab 200mg |
|-----------------------------|-------------------------------------------|--------------------------------------------|--------------------------------------------|-----------------------------------------------------------------|
| Subject group type          | Reporting group                           | Reporting group                            | Reporting group                            | Reporting group                                                 |
| Number of subjects analysed | 3                                         | 3                                          | 13                                         | 13                                                              |
| Units: Participants         | 3                                         | 3                                          | 13                                         | 13                                                              |

| End point values            | Part 2: Local Radiation, G100 20µg/lesion in Large Tumors | Part 3: Local Radiation + G100 20µg/lesion | Part 4: G100 20µg/lesion and Pembrolizumab 200mg |  |
|-----------------------------|-----------------------------------------------------------|--------------------------------------------|--------------------------------------------------|--|
| Subject group type          | Reporting group                                           | Reporting group                            | Reporting group                                  |  |
| Number of subjects analysed | 4                                                         | 14                                         | 1                                                |  |
| Units: Participants         | 4                                                         | 14                                         | 1                                                |  |

### Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants Who Discontinued Study Drug Due to an Adverse Event

|                 |                                                                                           |
|-----------------|-------------------------------------------------------------------------------------------|
| End point title | Number of Participants Who Discontinued Study Drug Due to an Adverse Event <sup>[2]</sup> |
|-----------------|-------------------------------------------------------------------------------------------|

End point description:

An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The analysis population included all enrolled participants who received at least 1 injection of G100 after standard local radiation.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to approximately 105 weeks

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned or performed for this endpoint.

| End point values            | Part 1: Local Radiation + G100 5µg/lesion | Part 1: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion+P embrolizumab 200mg |
|-----------------------------|-------------------------------------------|--------------------------------------------|--------------------------------------------|-----------------------------------------------------------------|
| Subject group type          | Reporting group                           | Reporting group                            | Reporting group                            | Reporting group                                                 |
| Number of subjects analysed | 3                                         | 3                                          | 13                                         | 13                                                              |
| Units: Participants         | 0                                         | 0                                          | 0                                          | 2                                                               |

| <b>End point values</b>     | Part 2: Local Radiation, G100 20µg/lesion in Large Tumors | Part 3: Local Radiation + G100 20µg/lesion | Part 4: G100 20µg/lesion and Pembrolizumab 200mg |  |
|-----------------------------|-----------------------------------------------------------|--------------------------------------------|--------------------------------------------------|--|
| Subject group type          | Reporting group                                           | Reporting group                            | Reporting group                                  |  |
| Number of subjects analysed | 4                                                         | 14                                         | 1                                                |  |
| Units: Participants         | 0                                                         | 1                                          | 0                                                |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Response Rate (ORR) by Immune-related Response Criteria (irRC)

|                 |                                                                        |
|-----------------|------------------------------------------------------------------------|
| End point title | Overall Response Rate (ORR) by Immune-related Response Criteria (irRC) |
|-----------------|------------------------------------------------------------------------|

End point description:

Overall response rate was defined as participants with best overall response of immune-related complete response (irCR) or immune-related partial response (irPR). irRC requires confirmatory restaging to determine if tumor size increase is due to true progression instead of immune inflammation and that new lesions add to tumor size calculations are not determinants of progressive disease by themselves. An irCR is the disappearance of all lesions, and no new lesions; an irPR is a  $\geq 50\%$  drop in tumour burden from baseline; and immune related Progressive Disease (irPD) is a  $\geq 25\%$  increase in tumour burden from the lowest level recorded. Everything else is considered immune-related Stable Disease (irSD). Tumor staging using bi-dimensional measurements was performed by CT or MRI. The analysis population included all enrolled participants without major protocol deviations, who received at least 1 injection of G100, and had baseline and at least 1 post baseline disease assessment.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to approximately 42 months

| <b>End point values</b>     | Part 1: Local Radiation + G100 5µg/lesion | Part 1: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion+P embrolizumab 200mg |
|-----------------------------|-------------------------------------------|--------------------------------------------|--------------------------------------------|-----------------------------------------------------------------|
| Subject group type          | Reporting group                           | Reporting group                            | Reporting group                            | Reporting group                                                 |
| Number of subjects analysed | 3                                         | 3                                          | 13                                         | 13                                                              |
| Units: Participants         |                                           |                                            |                                            |                                                                 |
| Complete Response (irCR)    | 0                                         | 0                                          | 0                                          | 0                                                               |
| Partial Response (irPR)     | 1                                         | 2                                          | 3                                          | 6                                                               |
| Stable Disease (irSD)       | 2                                         | 1                                          | 8                                          | 6                                                               |
| Progressive Disease (irPD)  | 0                                         | 0                                          | 2                                          | 1                                                               |

| End point values            | Part 2: Local Radiation, G100 20µg/lesion in Large Tumors | Part 3: Local Radiation + G100 20µg/lesion | Part 4: G100 20µg/lesion and Pembrolizumab 200mg |  |
|-----------------------------|-----------------------------------------------------------|--------------------------------------------|--------------------------------------------------|--|
| Subject group type          | Reporting group                                           | Reporting group                            | Reporting group                                  |  |
| Number of subjects analysed | 4                                                         | 14                                         | 1                                                |  |
| Units: Participants         |                                                           |                                            |                                                  |  |
| Complete Response (irCR)    | 0                                                         | 0                                          | 0                                                |  |
| Partial Response (irPR)     | 1                                                         | 6                                          | 0                                                |  |
| Stable Disease (irSD)       | 3                                                         | 7                                          | 1                                                |  |
| Progressive Disease (irPD)  | 0                                                         | 1                                          | 0                                                |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Clinical Benefit Rate (CBR) Using Immune-related Response Criteria (irRC)

|                 |                                                                           |
|-----------------|---------------------------------------------------------------------------|
| End point title | Clinical Benefit Rate (CBR) Using Immune-related Response Criteria (irRC) |
|-----------------|---------------------------------------------------------------------------|

End point description:

Clinical benefit rate (CBR) was defined as the number and percent of participants with best overall response of Immune related Response Criteria (irRC); complete response, partial response or stable disease (irCR+irPR+irSD). irRC requires confirmatory restaging to determine if tumor size increase is due to true progression instead of immune inflammation and that new lesions add to tumor size calculations and are not determinants of progressive disease by themselves. irCR is the disappearance of all lesions, and no new lesions; irPR is a  $\geq 50\%$  drop in tumor burden from baseline; and immune-related Progressive Disease (irPD) is a  $\geq 25\%$  increase in tumor burden from the lowest level recorded. Everything else is considered irSD. The analysis population included all enrolled participants without major protocol deviations, who received at least 1 injection of G100, and had baseline and at least 1 post-baseline disease assessment.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to approximately 42 months

| End point values                 | Part 1: Local Radiation + G100 5µg/lesion | Part 1: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion+P embrolizumab 200mg |
|----------------------------------|-------------------------------------------|--------------------------------------------|--------------------------------------------|-----------------------------------------------------------------|
| Subject group type               | Reporting group                           | Reporting group                            | Reporting group                            | Reporting group                                                 |
| Number of subjects analysed      | 3                                         | 3                                          | 13                                         | 13                                                              |
| Units: Percent of participants   |                                           |                                            |                                            |                                                                 |
| number (confidence interval 95%) | 100 (29.2 to 100)                         | 100 (29.2 to 100)                          | 84.6 (54.6 to 98.1)                        | 92.3 (64.0 to 99.8)                                             |

| End point values | Part 2: Local Radiation, | Part 3: Local Radiation + | Part 4: G100 20µg/lesion |  |
|------------------|--------------------------|---------------------------|--------------------------|--|
|------------------|--------------------------|---------------------------|--------------------------|--|

|                                  | G100<br>20µg/lesion in<br>Large Tumors | G100<br>20µg/lesion | and<br>Pembrolizumab<br>200mg |  |
|----------------------------------|----------------------------------------|---------------------|-------------------------------|--|
| Subject group type               | Reporting group                        | Reporting group     | Reporting group               |  |
| Number of subjects analysed      | 4                                      | 14                  | 1                             |  |
| Units: Percent of participants   |                                        |                     |                               |  |
| number (confidence interval 95%) | 100 (39.8 to 100)                      | 92.9 (66.1 to 99.8) | 100 (2.5 to 100)              |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Clinical Benefit Rate (CBR) Using International Working Group (IWG) Criteria

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                              |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Clinical Benefit Rate (CBR) Using International Working Group (IWG) Criteria |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                              |
| Clinical benefit rate (CBR) was all participants with best overall response of complete response, partial response or stable disease (CR+PR+SD). The IWG criteria (Cheson et al 2014) for a CR is a complete radiologic response (target nodes/nodal masses must regress to $\leq 1.5$ cm in longest transverse diameter (LDi), no extralymphatic sites of disease, and no new tumors. A PR is a $\geq 50\%$ decrease in SPD (sum of the product of the perpendicular diameters for multiple tumors) of up to 6 target measurable nodes and extranodal sites, spleen must have regressed by $> 50\%$ in length beyond normal, and no new tumors. Stable disease is a $< 50\%$ decrease from baseline in SPD of up to 6 dominant, measurable nodes and extranodal sites; no criteria for progressive disease are met, and no new tumors. The analysis population included all enrolled participants without major protocol deviations, who received at least 1 injection of G100, and had baseline and at least 1 post-baseline disease assessment. |                                                                              |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Secondary                                                                    |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                              |
| Up to approximately 42 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                              |

| End point values                  | Part 1: Local<br>Radiation +<br>G100<br>5µg/lesion | Part 1: Local<br>Radiation +<br>G100<br>10µg/lesion | Part 2: Local<br>Radiation +<br>G100<br>10µg/lesion | Part 2: Local<br>Radiation +<br>G100<br>10µg/lesion+P<br>embrolizumab<br>200mg |
|-----------------------------------|----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|--------------------------------------------------------------------------------|
| Subject group type                | Reporting group                                    | Reporting group                                     | Reporting group                                     | Reporting group                                                                |
| Number of subjects analysed       | 3                                                  | 3                                                   | 13                                                  | 13                                                                             |
| Units: Percentage of participants |                                                    |                                                     |                                                     |                                                                                |
| number (confidence interval 95%)  | 100 (29.2 to 100)                                  | 100 (29.2 to 100)                                   | 84.6 (54.6 to 98.1)                                 | 92.3 (64.0 to 99.8)                                                            |

| End point values | Part 2: Local<br>Radiation,<br>G100<br>20µg/lesion in<br>Large Tumors | Part 3: Local<br>Radiation +<br>G100<br>20µg/lesion | Part 4: G100<br>20µg/lesion<br>and<br>Pembrolizumab<br>200mg |  |
|------------------|-----------------------------------------------------------------------|-----------------------------------------------------|--------------------------------------------------------------|--|
|------------------|-----------------------------------------------------------------------|-----------------------------------------------------|--------------------------------------------------------------|--|

| Subject group type                | Reporting group   | Reporting group     | Reporting group  |  |
|-----------------------------------|-------------------|---------------------|------------------|--|
| Number of subjects analysed       | 4                 | 14                  | 1                |  |
| Units: Percentage of participants |                   |                     |                  |  |
| number (confidence interval 95%)  | 100 (39.8 to 100) | 78.6 (49.2 to 95.3) | 100 (2.5 to 100) |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Duration of Response (DOR) by Immune-related Response Criteria (irRC)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                       |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Duration of Response (DOR) by Immune-related Response Criteria (irRC) |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                       |
| Duration of response (DOR) was defined as the time interval between the date of the earliest qualifying confirmed/unconfirmed response using irRC and the date of disease progression (PD) or death for any cause, whichever occurs first. DOR in months was calculated as: (date of PD or death minus date of first confirmed/unconfirmed irCR/CR or irPR/PR + 1)/30.4375. DOR analysis included only participants with confirmed/unconfirmed response of irCR/irPR using irRC. Immune-related Progressive Disease (irPD) is a $\geq 25\%$ increase in tumor burden from the lowest level recorded. Median DOR with the corresponding two-sided 95% CI was estimated using the Kaplan-Meier method in each treatment group. The analysis population included all enrolled participants who received at least 1 injection of G100 after standard local radiation and had a confirmed/unconfirmed response of irCR/irPR using irRC. |                                                                       |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Secondary                                                             |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                       |
| Up to approximately 42 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                       |

| End point values              | Part 1: Local Radiation + G100 5µg/lesion | Part 1: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg |
|-------------------------------|-------------------------------------------|--------------------------------------------|--------------------------------------------|----------------------------------------------------------------|
| Subject group type            | Reporting group                           | Reporting group                            | Reporting group                            | Reporting group                                                |
| Number of subjects analysed   | 1                                         | 1                                          | 3 <sup>[3]</sup>                           | 4                                                              |
| Units: Months                 |                                           |                                            |                                            |                                                                |
| median (full range (min-max)) | 1.8 (1.8 to 1.8)                          | 15.6 (15.6 to 15.6)                        | 9999 (9999 to 9999)                        | 18.4 (3.8 to 27.2)                                             |

Notes:

[3] - "9999" - Median DOR was not reached by the time of last disease assessment.

| End point values              | Part 2: Local Radiation, G100 20µg/lesion in Large Tumors | Part 3: Local Radiation + G100 20µg/lesion | Part 4: G100 20µg/lesion and Pembrolizumab 200mg |  |
|-------------------------------|-----------------------------------------------------------|--------------------------------------------|--------------------------------------------------|--|
| Subject group type            | Reporting group                                           | Reporting group                            | Reporting group                                  |  |
| Number of subjects analysed   | 1 <sup>[4]</sup>                                          | 5                                          | 0 <sup>[5]</sup>                                 |  |
| Units: Months                 |                                                           |                                            |                                                  |  |
| median (full range (min-max)) | 9999 (9999 to 9999)                                       | 5.6 (2.8 to 16.1)                          | ( to )                                           |  |

Notes:

[4] - "9999" - Median DOR min./max. was not reached by the time of last disease assessment.

[5] - No DOR data was available for this participant.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Duration of Clinical Benefit by Immune-related Response Criteria (irRC)

|                 |                                                                         |
|-----------------|-------------------------------------------------------------------------|
| End point title | Duration of Clinical Benefit by Immune-related Response Criteria (irRC) |
|-----------------|-------------------------------------------------------------------------|

End point description:

Duration of clinical benefit was defined as the time interval between the date of the earliest qualifying confirmed/unconfirmed best response using irRC and the date of progressive disease (PD) or death for any cause, whichever occurred first. Duration of clinical benefit in months was calculated as: (date of PD or death – date of first confirmed/unconfirmed irCR/irPR or irSD + 1)/30.4375. Duration of clinical benefit included only participants with confirmed/unconfirmed response of irCR/irPR or irSD using irRC. Participants without progression, symptomatic deterioration, or death were censored at the date of the last tumor assessment. Median duration of clinical benefit and 95% CI were estimated using the Kaplan Meier method. The analysis population included all enrolled participants who received at least 1 injection of G100 after standard local radiation and had a confirmed/unconfirmed response of irCR/irPR or irSD using irRC.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to approximately 42 months

| End point values              | Part 1: Local Radiation + G100 5µg/lesion | Part 1: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg |
|-------------------------------|-------------------------------------------|--------------------------------------------|--------------------------------------------|----------------------------------------------------------------|
| Subject group type            | Reporting group                           | Reporting group                            | Reporting group                            | Reporting group                                                |
| Number of subjects analysed   | 3                                         | 3                                          | 11                                         | 12                                                             |
| Units: Months                 |                                           |                                            |                                            |                                                                |
| median (full range (min-max)) | 2.5 (1.8 to 3.4)                          | 20.8 (0.0 to 26.0)                         | 6.9 (0.0 to 16.2)                          | 9.2 (2.8 to 27.2)                                              |

| End point values              | Part 2: Local Radiation, G100 20µg/lesion in Large Tumors | Part 3: Local Radiation + G100 20µg/lesion | Part 4: G100 20µg/lesion and Pembrolizumab 200mg |  |
|-------------------------------|-----------------------------------------------------------|--------------------------------------------|--------------------------------------------------|--|
| Subject group type            | Reporting group                                           | Reporting group                            | Reporting group                                  |  |
| Number of subjects analysed   | 4                                                         | 13                                         | 0 <sup>[6]</sup>                                 |  |
| Units: Months                 |                                                           |                                            |                                                  |  |
| median (full range (min-max)) | 7.2 (0.0 to 20.1)                                         | 4.3 (0.0 to 20.0)                          | ( to )                                           |  |

Notes:

[6] - No Duration of Clinical Benefit data was available for this participant.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Progression-free Survival (PFS) by Immune-related Response Criteria (irRC)

|                 |                                                                            |
|-----------------|----------------------------------------------------------------------------|
| End point title | Progression-free Survival (PFS) by Immune-related Response Criteria (irRC) |
|-----------------|----------------------------------------------------------------------------|

End point description:

PFS was defined as time from date of first study treatment to date of first disease progression (a  $\geq 25\%$  increase in tumor burden from the lowest level recorded) by irRC criteria, symptomatic deterioration, or death due to any cause, whichever occurred first. Participants without progression, symptomatic deterioration, or death were censored at the date of the last tumor assessment. Progression-free survival in months is calculated as: (date of first progression, symptomatic deterioration, or death [any reason] – date of first dose +1)/30.4375. The irRC modification required a PD confirmation no less than 4 weeks from first documentation of PD. Summary of PFS including median, 95% CI was estimated using the Kaplan-Meier method. The analysis population included all enrolled participants without major protocol deviations, who received at least 1 injection of G100, and had baseline and at least 1 post-baseline disease assessment.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to approximately 42 months

| End point values              | Part 1: Local Radiation + G100 5µg/lesion | Part 1: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg |
|-------------------------------|-------------------------------------------|--------------------------------------------|--------------------------------------------|----------------------------------------------------------------|
| Subject group type            | Reporting group                           | Reporting group                            | Reporting group                            | Reporting group                                                |
| Number of subjects analysed   | 3                                         | 3                                          | 13                                         | 13                                                             |
| Units: Months                 |                                           |                                            |                                            |                                                                |
| median (full range (min-max)) | 4.9 (3.7 to 5.3)                          | 22.6 (1.9 to 27.7)                         | 7.4 (1.7 to 33.7)                          | 11.1 (1.9 to 32.5)                                             |

| End point values              | Part 2: Local Radiation, G100 20µg/lesion in Large Tumors | Part 3: Local Radiation + G100 20µg/lesion | Part 4: G100 20µg/lesion and Pembrolizumab 200mg |  |
|-------------------------------|-----------------------------------------------------------|--------------------------------------------|--------------------------------------------------|--|
| Subject group type            | Reporting group                                           | Reporting group                            | Reporting group                                  |  |
| Number of subjects analysed   | 4                                                         | 14                                         | 1 <sup>[7]</sup>                                 |  |
| Units: Months                 |                                                           |                                            |                                                  |  |
| median (full range (min-max)) | 9.8 (1.9 to 21.9)                                         | 7.7 (1.4 to 22.6)                          | 9999 (9999 to 9999)                              |  |

Notes:

[7] - "9999" - median PFS was not reached (no disease progression or death).

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Survival (OS)

|                 |                       |
|-----------------|-----------------------|
| End point title | Overall Survival (OS) |
|-----------------|-----------------------|

End point description:

Overall Survival (OS) was defined as the time from date of first study treatment to death due to any cause. Overall survival in months was calculated as: ([date of death – date of first dose] + 1)/30.4375. Participants who were alive at the end of study were censored at the last date the participant was known to be alive or data analysis cutoff date, whichever was earlier. Summary of OS including median, 95% CI was estimated using the Kaplan-Meier method. The analysis population included all enrolled participants without major protocol deviations, who received at least 1 injection of G100, and had baseline and at least 1 post-baseline disease assessment.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to approximately 42 months

| End point values              | Part 1: Local Radiation + G100 5µg/lesion | Part 1: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg |
|-------------------------------|-------------------------------------------|--------------------------------------------|--------------------------------------------|----------------------------------------------------------------|
| Subject group type            | Reporting group                           | Reporting group                            | Reporting group                            | Reporting group                                                |
| Number of subjects analysed   | 3 <sup>[8]</sup>                          | 3 <sup>[9]</sup>                           | 13 <sup>[10]</sup>                         | 13 <sup>[11]</sup>                                             |
| Units: Months                 |                                           |                                            |                                            |                                                                |
| median (full range (min-max)) | 9999 (9999 to 9999)                       | 9999 (9999 to 9999)                        | 9999 (9999 to 9999)                        | 9999 (9999 to 9999)                                            |

Notes:

[8] - "9999" - median OS was not reached (insufficient number of deaths).

[9] - "9999" - median OS was not reached (insufficient number of deaths).

[10] - "9999" - median OS was not reached (insufficient number of deaths).

[11] - "9999" - median OS was not reached (insufficient number of deaths).

| End point values              | Part 2: Local Radiation, G100 20µg/lesion in Large Tumors | Part 3: Local Radiation + G100 20µg/lesion | Part 4: G100 20µg/lesion and Pembrolizumab 200mg |  |
|-------------------------------|-----------------------------------------------------------|--------------------------------------------|--------------------------------------------------|--|
| Subject group type            | Reporting group                                           | Reporting group                            | Reporting group                                  |  |
| Number of subjects analysed   | 4 <sup>[12]</sup>                                         | 14 <sup>[13]</sup>                         | 1 <sup>[14]</sup>                                |  |
| Units: Months                 |                                                           |                                            |                                                  |  |
| median (full range (min-max)) | 9999 (9999 to 9999)                                       | 9999 (9999 to 9999)                        | 9999 (9999 to 9999)                              |  |

Notes:

[12] - "9999" - median OS was not reached (insufficient number of deaths).

[13] - "9999" - median OS was not reached (insufficient number of deaths).

[14] - "9999" - median OS was not reached (insufficient number of deaths).

## Statistical analyses

No statistical analyses for this end point

### Secondary: Overall Tumor Response Based on irRC Abscopal Sites

|                 |                                                     |
|-----------------|-----------------------------------------------------|
| End point title | Overall Tumor Response Based on irRC Abscopal Sites |
|-----------------|-----------------------------------------------------|

End point description:

Abscopal tumor responses were assessed in non-treated, distal tumor sites. Immune-related Response Criteria irRC requires confirmatory restaging to determine if tumor size increase is due to true progression instead of immune inflammation and that new lesions add to tumor size calculations are not determinants of progressive disease. An immune-related Complete Response (irCR) is the disappearance of all lesions, and no new lesions; an immune-related Partial Response (irPR) is a  $\geq 50\%$  drop in tumour burden from baseline; and immune related Progressive Disease (irPD) is a  $\geq 25\%$  increase in tumour burden from the lowest level recorded. Everything else was considered immune-related Stable Disease (irSD). Tumor staging by CT or MRI was performed. The analysis population included all enrolled participants without major protocol deviations, who received at least 1 injection of G100, and had baseline and at least 1 post baseline disease assessment.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to approximately 42 months

| End point values            | Part 1: Local Radiation + G100 5µg/lesion | Part 1: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg |
|-----------------------------|-------------------------------------------|--------------------------------------------|--------------------------------------------|----------------------------------------------------------------|
| Subject group type          | Reporting group                           | Reporting group                            | Reporting group                            | Reporting group                                                |
| Number of subjects analysed | 3                                         | 3                                          | 13                                         | 13                                                             |
| Units: Participants         |                                           |                                            |                                            |                                                                |
| Complete Response (irCR)    | 0                                         | 0                                          | 0                                          | 0                                                              |
| Partial Response (irPR)     | 0                                         | 1                                          | 4                                          | 3                                                              |
| Stable Disease (irSD)       | 1                                         | 2                                          | 4                                          | 8                                                              |
| Progressive Disease (irPD)  | 1                                         | 0                                          | 4                                          | 2                                                              |

| End point values            | Part 2: Local Radiation, G100 20µg/lesion in Large Tumors | Part 3: Local Radiation + G100 20µg/lesion | Part 4: G100 20µg/lesion and Pembrolizumab 200mg |  |
|-----------------------------|-----------------------------------------------------------|--------------------------------------------|--------------------------------------------------|--|
| Subject group type          | Reporting group                                           | Reporting group                            | Reporting group                                  |  |
| Number of subjects analysed | 4                                                         | 14                                         | 1                                                |  |
| Units: Participants         |                                                           |                                            |                                                  |  |
| Complete Response (irCR)    | 0                                                         | 0                                          | 0                                                |  |
| Partial Response (irPR)     | 0                                                         | 3                                          | 0                                                |  |

|                            |   |   |   |  |
|----------------------------|---|---|---|--|
| Stable Disease (irSD)      | 3 | 9 | 1 |  |
| Progressive Disease (irPD) | 1 | 2 | 0 |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to Response for Complete Response and Partial Response Participants

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                          |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Time to Response for Complete Response and Partial Response Participants |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                          |
| Time to Response for CR and PR participants was defined as time from date of first study treatment to the date of CR or PR response first documented. Complete Response (irCR) is the disappearance of all lesions, and no new lesions; an immune-related Partial Response (irPR) is a $\geq 50\%$ drop in tumor burden from baseline. Time to response in months was calculated as: (date of first CR or PR minus date of first dose + 1)/30.4375. Summary of Time to Response including median and range was estimated using Kaplan-Meier method. The analysis population included all enrolled participants without major protocol deviations, who received at least 1 injection of G100, and had baseline and at least 1 post-baseline disease assessment. |                                                                          |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Secondary                                                                |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                          |
| Up to 42 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                          |

| End point values              | Part 1: Local Radiation + G100 5µg/lesion | Part 1: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg |
|-------------------------------|-------------------------------------------|--------------------------------------------|--------------------------------------------|----------------------------------------------------------------|
| Subject group type            | Reporting group                           | Reporting group                            | Reporting group                            | Reporting group                                                |
| Number of subjects analysed   | 1                                         | 2                                          | 3                                          | 6                                                              |
| Units: Months                 |                                           |                                            |                                            |                                                                |
| median (full range (min-max)) | 1.9 (1.9 to 1.9)                          | 1.9 (1.9 to 1.9)                           | 2.3 (1.7 to 18.1)                          | 4.1 (2.2 to 14.1)                                              |

| End point values              | Part 2: Local Radiation, G100 20µg/lesion in Large Tumors | Part 3: Local Radiation + G100 20µg/lesion | Part 4: G100 20µg/lesion and Pembrolizumab 200mg |  |
|-------------------------------|-----------------------------------------------------------|--------------------------------------------|--------------------------------------------------|--|
| Subject group type            | Reporting group                                           | Reporting group                            | Reporting group                                  |  |
| Number of subjects analysed   | 1                                                         | 6                                          | 0 <sup>[15]</sup>                                |  |
| Units: Months                 |                                                           |                                            |                                                  |  |
| median (full range (min-max)) | 2.6 (2.6 to 2.6)                                          | 5.2 (1.9 to 7.3)                           | ( to )                                           |  |

Notes:

[15] - No Time to Response data was available for this participant.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Time to Next Treatment (TTNT)

|                 |                               |
|-----------------|-------------------------------|
| End point title | Time to Next Treatment (TTNT) |
|-----------------|-------------------------------|

End point description:

Time to next treatment was defined as the time from the date of first study treatment to the start date of subsequent therapy after PD. Immune-related Progressive Disease (irPD) is a  $\geq 25\%$  increase in tumor burden from the lowest level recorded. Participants who did not receive subsequent therapy after PD were censored at the date of last contact or death. Summary of time to next treatment including median and range was estimated using the Kaplan-Meier method. The analysis population included all enrolled participants without major protocol deviations, who received at least 1 injection of G100, and had baseline and at least 1 post-baseline disease assessment.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to approximately 42 months

| End point values              | Part 1: Local Radiation + G100 5µg/lesion | Part 1: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion | Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg |
|-------------------------------|-------------------------------------------|--------------------------------------------|--------------------------------------------|----------------------------------------------------------------|
| Subject group type            | Reporting group                           | Reporting group                            | Reporting group                            | Reporting group                                                |
| Number of subjects analysed   | 3                                         | 1 <sup>[16]</sup>                          | 8                                          | 6 <sup>[17]</sup>                                              |
| Units: Months                 |                                           |                                            |                                            |                                                                |
| median (full range (min-max)) | 5.4 (4.1 to 6.6)                          | 9999 (9999 to 9999)                        | 12.7 (1.9 to 33.7)                         | 9999 (9999 to 9999)                                            |

Notes:

[16] - "9999" - median TTNT was not reached (insufficient number of treatments by time of last assessment).

[17] - "9999" - median was not reached (insufficient number of treatments by time of last assessment).

| End point values              | Part 2: Local Radiation, G100 20µg/lesion in Large Tumors | Part 3: Local Radiation + G100 20µg/lesion | Part 4: G100 20µg/lesion and Pembrolizumab 200mg |  |
|-------------------------------|-----------------------------------------------------------|--------------------------------------------|--------------------------------------------------|--|
| Subject group type            | Reporting group                                           | Reporting group                            | Reporting group                                  |  |
| Number of subjects analysed   | 1 <sup>[18]</sup>                                         | 6 <sup>[19]</sup>                          | 0 <sup>[20]</sup>                                |  |
| Units: Months                 |                                                           |                                            |                                                  |  |
| median (full range (min-max)) | 9999 (9999 to 9999)                                       | 9999 (9999 to 9999)                        | ( to )                                           |  |

Notes:

[18] - "9999" - median TTNT was not reached (insufficient number of treatments by time of last assessment).

[19] - "9999" - median TTNT was not reached (insufficient number of treatments by time of last assessment).

[20] - This participant did not have irPD data.

## **Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to approximately 42 months

Adverse event reporting additional description:

The analysis population included all treated participants. Medical Dictionary for Regulatory Activities (MedDRA) terms "Neoplasm progression", "Malignant neoplasm progression" and "Disease progression" not related to study treatment were excluded as AEs as considered due to cancer progression. No participant was enrolled or dosed in Part 5.

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 22.0 |
|--------------------|------|

### Reporting groups

|                       |                                            |
|-----------------------|--------------------------------------------|
| Reporting group title | Part 2: Local Radiation + G100 10µg/lesion |
|-----------------------|--------------------------------------------|

Reporting group description:

Part 2: Local radiation and G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.

|                       |                                            |
|-----------------------|--------------------------------------------|
| Reporting group title | Part 1: Local Radiation + G100 10µg/lesion |
|-----------------------|--------------------------------------------|

Reporting group description:

Part 1 + Part 2: Local radiation and G100 at 10µg/lesion administered IT into accessible lesions for up to 8 weeks.

|                       |                                           |
|-----------------------|-------------------------------------------|
| Reporting group title | Part 1: Local Radiation + G100 5µg/lesion |
|-----------------------|-------------------------------------------|

Reporting group description:

Part 1: Local radiation and G100 [glucopyranosyl lipid A stable emulsion, GLA-SE] at 5µg/lesion administered intratumoral (IT) into accessible lesions for up to 8 weeks.

|                       |                                                                |
|-----------------------|----------------------------------------------------------------|
| Reporting group title | Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg |
|-----------------------|----------------------------------------------------------------|

Reporting group description:

Part 2: Local radiation and G100 at 10µg/lesion administered IT into accessible tumors for up to 8 weeks; pembrolizumab 200mg intravenously (IV) administered every 3 weeks (Q3W) IV for up to 2 years.

|                       |                                                            |
|-----------------------|------------------------------------------------------------|
| Reporting group title | Part 2: Local Radiation, G100 20 µg/lesion in Large Tumors |
|-----------------------|------------------------------------------------------------|

Reporting group description:

Part 2: Local radiation and G100 at 20 µg/lesion administered IT into accessible large tumors (injectable lymphoma mass(es) ≥ 4 cm in total size) for up to 8 weeks.

|                       |                                                  |
|-----------------------|--------------------------------------------------|
| Reporting group title | Part 4: G100 20µg/lesion and pembrolizumab 200mg |
|-----------------------|--------------------------------------------------|

Reporting group description:

Part 4: G100 at 20µg/lesion administered IT into accessible lesions for up to 8 weeks and pembrolizumab 200mg IV and administered Q3W for up to 2 years.

|                       |                                            |
|-----------------------|--------------------------------------------|
| Reporting group title | Part 3: Local Radiation + G100 20µg/lesion |
|-----------------------|--------------------------------------------|

Reporting group description:

Part 3: Local radiation and G100 at 20µg/lesion administered IT into accessible lesions for up to 8 weeks.

| Serious adverse events                            | Part 2: Local Radiation + G100 10µg/lesion | Part 1: Local Radiation + G100 10µg/lesion | Part 1: Local Radiation + G100 5µg/lesion |
|---------------------------------------------------|--------------------------------------------|--------------------------------------------|-------------------------------------------|
| Total subjects affected by serious adverse events |                                            |                                            |                                           |
| subjects affected / exposed                       | 1 / 13 (7.69%)                             | 0 / 3 (0.00%)                              | 0 / 3 (0.00%)                             |

|                                                      |                                                                |                                                            |                                                  |
|------------------------------------------------------|----------------------------------------------------------------|------------------------------------------------------------|--------------------------------------------------|
| number of deaths (all causes)                        | 1                                                              | 0                                                          | 0                                                |
| number of deaths resulting from adverse events       | 0                                                              | 0                                                          | 0                                                |
| Injury, poisoning and procedural complications       |                                                                |                                                            |                                                  |
| Multiple fractures                                   |                                                                |                                                            |                                                  |
| subjects affected / exposed                          | 0 / 13 (0.00%)                                                 | 0 / 3 (0.00%)                                              | 0 / 3 (0.00%)                                    |
| occurrences causally related to treatment / all      | 0 / 0                                                          | 0 / 0                                                      | 0 / 0                                            |
| deaths causally related to treatment / all           | 0 / 0                                                          | 0 / 0                                                      | 0 / 0                                            |
| General disorders and administration site conditions |                                                                |                                                            |                                                  |
| Pyrexia                                              |                                                                |                                                            |                                                  |
| subjects affected / exposed                          | 0 / 13 (0.00%)                                                 | 0 / 3 (0.00%)                                              | 0 / 3 (0.00%)                                    |
| occurrences causally related to treatment / all      | 0 / 0                                                          | 0 / 0                                                      | 0 / 0                                            |
| deaths causally related to treatment / all           | 0 / 0                                                          | 0 / 0                                                      | 0 / 0                                            |
| Gastrointestinal disorders                           |                                                                |                                                            |                                                  |
| Abdominal pain upper                                 |                                                                |                                                            |                                                  |
| subjects affected / exposed                          | 0 / 13 (0.00%)                                                 | 0 / 3 (0.00%)                                              | 0 / 3 (0.00%)                                    |
| occurrences causally related to treatment / all      | 0 / 0                                                          | 0 / 0                                                      | 0 / 0                                            |
| deaths causally related to treatment / all           | 0 / 0                                                          | 0 / 0                                                      | 0 / 0                                            |
| Endocrine disorders                                  |                                                                |                                                            |                                                  |
| Adrenal insufficiency                                |                                                                |                                                            |                                                  |
| subjects affected / exposed                          | 0 / 13 (0.00%)                                                 | 0 / 3 (0.00%)                                              | 0 / 3 (0.00%)                                    |
| occurrences causally related to treatment / all      | 0 / 0                                                          | 0 / 0                                                      | 0 / 0                                            |
| deaths causally related to treatment / all           | 0 / 0                                                          | 0 / 0                                                      | 0 / 0                                            |
| Infections and infestations                          |                                                                |                                                            |                                                  |
| Septic shock                                         |                                                                |                                                            |                                                  |
| subjects affected / exposed                          | 1 / 13 (7.69%)                                                 | 0 / 3 (0.00%)                                              | 0 / 3 (0.00%)                                    |
| occurrences causally related to treatment / all      | 0 / 1                                                          | 0 / 0                                                      | 0 / 0                                            |
| deaths causally related to treatment / all           | 0 / 0                                                          | 0 / 0                                                      | 0 / 0                                            |
| <b>Serious adverse events</b>                        | Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg | Part 2: Local Radiation, G100 20 µg/lesion in Large Tumors | Part 4: G100 20µg/lesion and pembrolizumab 200mg |
| Total subjects affected by serious adverse events    |                                                                |                                                            |                                                  |
| subjects affected / exposed                          | 4 / 13 (30.77%)                                                | 0 / 4 (0.00%)                                              | 0 / 1 (0.00%)                                    |
| number of deaths (all causes)                        | 1                                                              | 0                                                          | 0                                                |
| number of deaths resulting from adverse events       | 0                                                              | 0                                                          | 0                                                |
| Injury, poisoning and procedural complications       |                                                                |                                                            |                                                  |

|                                                      |                |               |               |
|------------------------------------------------------|----------------|---------------|---------------|
| Multiple fractures                                   |                |               |               |
| subjects affected / exposed                          | 1 / 13 (7.69%) | 0 / 4 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 1          | 0 / 0         | 0 / 0         |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0         | 0 / 0         |
| General disorders and administration site conditions |                |               |               |
| Pyrexia                                              |                |               |               |
| subjects affected / exposed                          | 1 / 13 (7.69%) | 0 / 4 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 1          | 0 / 0         | 0 / 0         |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0         | 0 / 0         |
| Gastrointestinal disorders                           |                |               |               |
| Abdominal pain upper                                 |                |               |               |
| subjects affected / exposed                          | 1 / 13 (7.69%) | 0 / 4 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 1          | 0 / 0         | 0 / 0         |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0         | 0 / 0         |
| Endocrine disorders                                  |                |               |               |
| Adrenal insufficiency                                |                |               |               |
| subjects affected / exposed                          | 1 / 13 (7.69%) | 0 / 4 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all      | 1 / 1          | 0 / 0         | 0 / 0         |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0         | 0 / 0         |
| Infections and infestations                          |                |               |               |
| Septic shock                                         |                |               |               |
| subjects affected / exposed                          | 0 / 13 (0.00%) | 0 / 4 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0         | 0 / 0         |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0         | 0 / 0         |

|                                                   |                                            |  |  |
|---------------------------------------------------|--------------------------------------------|--|--|
| <b>Serious adverse events</b>                     | Part 3: Local Radiation + G100 20µg/lesion |  |  |
| Total subjects affected by serious adverse events |                                            |  |  |
| subjects affected / exposed                       | 0 / 14 (0.00%)                             |  |  |
| number of deaths (all causes)                     | 1                                          |  |  |
| number of deaths resulting from adverse events    | 0                                          |  |  |
| Injury, poisoning and procedural complications    |                                            |  |  |
| Multiple fractures                                |                                            |  |  |
| subjects affected / exposed                       | 0 / 14 (0.00%)                             |  |  |
| occurrences causally related to treatment / all   | 0 / 0                                      |  |  |
| deaths causally related to treatment / all        | 0 / 0                                      |  |  |

|                                                      |                |  |  |
|------------------------------------------------------|----------------|--|--|
| General disorders and administration site conditions |                |  |  |
| Pyrexia                                              |                |  |  |
| subjects affected / exposed                          | 0 / 14 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Gastrointestinal disorders                           |                |  |  |
| Abdominal pain upper                                 |                |  |  |
| subjects affected / exposed                          | 0 / 14 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Endocrine disorders                                  |                |  |  |
| Adrenal insufficiency                                |                |  |  |
| subjects affected / exposed                          | 0 / 14 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Infections and infestations                          |                |  |  |
| Septic shock                                         |                |  |  |
| subjects affected / exposed                          | 0 / 14 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                     | Part 2: Local Radiation + G100 10µg/lesion | Part 1: Local Radiation + G100 10µg/lesion | Part 1: Local Radiation + G100 5µg/lesion |
|-------------------------------------------------------|--------------------------------------------|--------------------------------------------|-------------------------------------------|
| Total subjects affected by non-serious adverse events |                                            |                                            |                                           |
| subjects affected / exposed                           | 13 / 13 (100.00%)                          | 3 / 3 (100.00%)                            | 3 / 3 (100.00%)                           |
| Vascular disorders                                    |                                            |                                            |                                           |
| Diastolic hypertension                                |                                            |                                            |                                           |
| subjects affected / exposed                           | 0 / 13 (0.00%)                             | 0 / 3 (0.00%)                              | 0 / 3 (0.00%)                             |
| occurrences (all)                                     | 0                                          | 0                                          | 0                                         |
| Embolism                                              |                                            |                                            |                                           |
| subjects affected / exposed                           | 0 / 13 (0.00%)                             | 0 / 3 (0.00%)                              | 0 / 3 (0.00%)                             |
| occurrences (all)                                     | 0                                          | 0                                          | 0                                         |
| Flushing                                              |                                            |                                            |                                           |

|                                                      |                |               |               |
|------------------------------------------------------|----------------|---------------|---------------|
| subjects affected / exposed                          | 1 / 13 (7.69%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                                    | 1              | 0             | 0             |
| Haematoma                                            |                |               |               |
| subjects affected / exposed                          | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                                    | 0              | 0             | 0             |
| Hot flush                                            |                |               |               |
| subjects affected / exposed                          | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                                    | 0              | 0             | 0             |
| Hypertension                                         |                |               |               |
| subjects affected / exposed                          | 1 / 13 (7.69%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                                    | 2              | 0             | 0             |
| Hypotension                                          |                |               |               |
| subjects affected / exposed                          | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                                    | 0              | 0             | 0             |
| Systolic hypertension                                |                |               |               |
| subjects affected / exposed                          | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                                    | 0              | 0             | 0             |
| Varicose vein                                        |                |               |               |
| subjects affected / exposed                          | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                                    | 0              | 0             | 0             |
| General disorders and administration site conditions |                |               |               |
| Administration site pain                             |                |               |               |
| subjects affected / exposed                          | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                                    | 0              | 0             | 0             |
| Asthenia                                             |                |               |               |
| subjects affected / exposed                          | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                                    | 0              | 0             | 0             |
| Chest pain                                           |                |               |               |
| subjects affected / exposed                          | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                                    | 0              | 0             | 0             |
| Chills                                               |                |               |               |
| subjects affected / exposed                          | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                                    | 0              | 0             | 0             |
| Fatigue                                              |                |               |               |

|                             |                 |                |                |
|-----------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 0 / 13 (0.00%)  | 2 / 3 (66.67%) | 1 / 3 (33.33%) |
| occurrences (all)           | 0               | 2              | 1              |
| Feeling hot                 |                 |                |                |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%)  |
| occurrences (all)           | 0               | 0              | 0              |
| Influenza like illness      |                 |                |                |
| subjects affected / exposed | 0 / 13 (0.00%)  | 1 / 3 (33.33%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 0               | 2              | 0              |
| Infusion site swelling      |                 |                |                |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%)  |
| occurrences (all)           | 0               | 0              | 0              |
| Injection site bruising     |                 |                |                |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 3 (0.00%)  | 1 / 3 (33.33%) |
| occurrences (all)           | 1               | 0              | 1              |
| Injection site discomfort   |                 |                |                |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%)  |
| occurrences (all)           | 1               | 0              | 0              |
| Injection site erythema     |                 |                |                |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%)  |
| occurrences (all)           | 0               | 0              | 0              |
| Injection site pain         |                 |                |                |
| subjects affected / exposed | 3 / 13 (23.08%) | 0 / 3 (0.00%)  | 0 / 3 (0.00%)  |
| occurrences (all)           | 5               | 0              | 0              |
| Injection site reaction     |                 |                |                |
| subjects affected / exposed | 1 / 13 (7.69%)  | 1 / 3 (33.33%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 5               | 1              | 0              |
| Injection site swelling     |                 |                |                |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%)  |
| occurrences (all)           | 1               | 0              | 0              |
| Oedema peripheral           |                 |                |                |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%)  |
| occurrences (all)           | 1               | 0              | 0              |
| Pain                        |                 |                |                |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%)  |
| occurrences (all)           | 0               | 0              | 0              |
| Peripheral swelling         |                 |                |                |

|                                                 |                 |               |               |
|-------------------------------------------------|-----------------|---------------|---------------|
| subjects affected / exposed                     | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                               | 0               | 0             | 0             |
| Pyrexia                                         |                 |               |               |
| subjects affected / exposed                     | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                               | 0               | 0             | 0             |
| Immune system disorders                         |                 |               |               |
| Drug hypersensitivity                           |                 |               |               |
| subjects affected / exposed                     | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                               | 0               | 0             | 0             |
| Seasonal allergy                                |                 |               |               |
| subjects affected / exposed                     | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                               | 0               | 0             | 0             |
| Reproductive system and breast disorders        |                 |               |               |
| Epididymal cyst                                 |                 |               |               |
| subjects affected / exposed                     | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                               | 0               | 0             | 0             |
| Oedema genital                                  |                 |               |               |
| subjects affected / exposed                     | 1 / 13 (7.69%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                               | 1               | 0             | 0             |
| Testicular atrophy                              |                 |               |               |
| subjects affected / exposed                     | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                               | 0               | 0             | 0             |
| Testis discomfort                               |                 |               |               |
| subjects affected / exposed                     | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                               | 0               | 0             | 0             |
| Vulvovaginal inflammation                       |                 |               |               |
| subjects affected / exposed                     | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                               | 0               | 0             | 0             |
| Respiratory, thoracic and mediastinal disorders |                 |               |               |
| Asthma                                          |                 |               |               |
| subjects affected / exposed                     | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                               | 0               | 0             | 0             |
| Cough                                           |                 |               |               |
| subjects affected / exposed                     | 2 / 13 (15.38%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                               | 2               | 0             | 0             |
| Dyspnoea                                        |                 |               |               |

|                             |                 |               |                |
|-----------------------------|-----------------|---------------|----------------|
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all)           | 1               | 0             | 1              |
| Nasal congestion            |                 |               |                |
| subjects affected / exposed | 2 / 13 (15.38%) | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 2               | 0             | 0              |
| Oropharyngeal pain          |                 |               |                |
| subjects affected / exposed | 4 / 13 (30.77%) | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 4               | 0             | 0              |
| Pleural effusion            |                 |               |                |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 1               | 0             | 0              |
| Productive cough            |                 |               |                |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 0               | 0             | 0              |
| Pulmonary congestion        |                 |               |                |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 0               | 0             | 0              |
| Sinus congestion            |                 |               |                |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 1               | 0             | 0              |
| Throat irritation           |                 |               |                |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 0               | 0             | 0              |
| Upper-airway cough syndrome |                 |               |                |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 0               | 0             | 0              |
| Psychiatric disorders       |                 |               |                |
| Depression                  |                 |               |                |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 0               | 0             | 0              |
| Insomnia                    |                 |               |                |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 0               | 0             | 0              |
| Libido decreased            |                 |               |                |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 0               | 0             | 0              |

|                                      |                 |                |               |
|--------------------------------------|-----------------|----------------|---------------|
| Restlessness                         |                 |                |               |
| subjects affected / exposed          | 0 / 13 (0.00%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%) |
| occurrences (all)                    | 0               | 0              | 0             |
| Sleep disorder                       |                 |                |               |
| subjects affected / exposed          | 0 / 13 (0.00%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%) |
| occurrences (all)                    | 0               | 0              | 0             |
| Investigations                       |                 |                |               |
| Alanine aminotransferase increased   |                 |                |               |
| subjects affected / exposed          | 1 / 13 (7.69%)  | 1 / 3 (33.33%) | 0 / 3 (0.00%) |
| occurrences (all)                    | 1               | 1              | 0             |
| Aspartate aminotransferase increased |                 |                |               |
| subjects affected / exposed          | 1 / 13 (7.69%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%) |
| occurrences (all)                    | 2               | 0              | 0             |
| Blast cell count increased           |                 |                |               |
| subjects affected / exposed          | 1 / 13 (7.69%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%) |
| occurrences (all)                    | 1               | 0              | 0             |
| Blood alkaline phosphatase increased |                 |                |               |
| subjects affected / exposed          | 1 / 13 (7.69%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%) |
| occurrences (all)                    | 2               | 0              | 0             |
| Blood bilirubin decreased            |                 |                |               |
| subjects affected / exposed          | 0 / 13 (0.00%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%) |
| occurrences (all)                    | 0               | 0              | 0             |
| Blood bilirubin increased            |                 |                |               |
| subjects affected / exposed          | 2 / 13 (15.38%) | 0 / 3 (0.00%)  | 0 / 3 (0.00%) |
| occurrences (all)                    | 2               | 0              | 0             |
| Blood creatinine decreased           |                 |                |               |
| subjects affected / exposed          | 0 / 13 (0.00%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%) |
| occurrences (all)                    | 0               | 0              | 0             |
| Blood creatinine increased           |                 |                |               |
| subjects affected / exposed          | 0 / 13 (0.00%)  | 1 / 3 (33.33%) | 0 / 3 (0.00%) |
| occurrences (all)                    | 0               | 1              | 0             |
| Blood glucose increased              |                 |                |               |
| subjects affected / exposed          | 0 / 13 (0.00%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%) |
| occurrences (all)                    | 0               | 0              | 0             |
| Breath sounds abnormal               |                 |                |               |

|                                                |                 |                |               |
|------------------------------------------------|-----------------|----------------|---------------|
| subjects affected / exposed                    | 1 / 13 (7.69%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%) |
| occurrences (all)                              | 1               | 0              | 0             |
| Haemoglobin increased                          |                 |                |               |
| subjects affected / exposed                    | 0 / 13 (0.00%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%) |
| occurrences (all)                              | 0               | 0              | 0             |
| Lymphocyte count decreased                     |                 |                |               |
| subjects affected / exposed                    | 2 / 13 (15.38%) | 1 / 3 (33.33%) | 0 / 3 (0.00%) |
| occurrences (all)                              | 3               | 1              | 0             |
| Neutrophil count decreased                     |                 |                |               |
| subjects affected / exposed                    | 1 / 13 (7.69%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%) |
| occurrences (all)                              | 2               | 0              | 0             |
| Platelet count decreased                       |                 |                |               |
| subjects affected / exposed                    | 2 / 13 (15.38%) | 0 / 3 (0.00%)  | 0 / 3 (0.00%) |
| occurrences (all)                              | 2               | 0              | 0             |
| White blood cell count decreased               |                 |                |               |
| subjects affected / exposed                    | 2 / 13 (15.38%) | 1 / 3 (33.33%) | 0 / 3 (0.00%) |
| occurrences (all)                              | 4               | 1              | 0             |
| Injury, poisoning and procedural complications |                 |                |               |
| Contusion                                      |                 |                |               |
| subjects affected / exposed                    | 0 / 13 (0.00%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%) |
| occurrences (all)                              | 0               | 0              | 0             |
| Expired product administered                   |                 |                |               |
| subjects affected / exposed                    | 0 / 13 (0.00%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%) |
| occurrences (all)                              | 0               | 0              | 0             |
| Fall                                           |                 |                |               |
| subjects affected / exposed                    | 0 / 13 (0.00%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%) |
| occurrences (all)                              | 0               | 0              | 0             |
| Procedural pain                                |                 |                |               |
| subjects affected / exposed                    | 1 / 13 (7.69%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%) |
| occurrences (all)                              | 1               | 0              | 0             |
| Radiation associated pain                      |                 |                |               |
| subjects affected / exposed                    | 0 / 13 (0.00%)  | 0 / 3 (0.00%)  | 0 / 3 (0.00%) |
| occurrences (all)                              | 0               | 0              | 0             |
| Radiation skin injury                          |                 |                |               |

|                                                                             |                     |                     |                    |
|-----------------------------------------------------------------------------|---------------------|---------------------|--------------------|
| subjects affected / exposed<br>occurrences (all)                            | 0 / 13 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0 |
| Skin laceration<br>subjects affected / exposed<br>occurrences (all)         | 0 / 13 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0 |
| Cardiac disorders                                                           |                     |                     |                    |
| Coronary artery disease<br>subjects affected / exposed<br>occurrences (all) | 0 / 13 (0.00%)<br>0 | 1 / 3 (33.33%)<br>1 | 0 / 3 (0.00%)<br>0 |
| Myocardial fibrosis<br>subjects affected / exposed<br>occurrences (all)     | 1 / 13 (7.69%)<br>1 | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0 |
| Sinus bradycardia<br>subjects affected / exposed<br>occurrences (all)       | 0 / 13 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0 |
| Tachycardia<br>subjects affected / exposed<br>occurrences (all)             | 0 / 13 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0 |
| Nervous system disorders                                                    |                     |                     |                    |
| Carpal tunnel syndrome<br>subjects affected / exposed<br>occurrences (all)  | 0 / 13 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0 |
| Dizziness<br>subjects affected / exposed<br>occurrences (all)               | 1 / 13 (7.69%)<br>1 | 1 / 3 (33.33%)<br>1 | 0 / 3 (0.00%)<br>0 |
| Dysgeusia<br>subjects affected / exposed<br>occurrences (all)               | 0 / 13 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0 |
| Headache<br>subjects affected / exposed<br>occurrences (all)                | 0 / 13 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0 |
| Neuropathy peripheral<br>subjects affected / exposed<br>occurrences (all)   | 1 / 13 (7.69%)<br>1 | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0 |
| Nystagmus                                                                   |                     |                     |                    |

|                                                                        |                     |                     |                     |
|------------------------------------------------------------------------|---------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)                       | 0 / 13 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  |
| Presyncope<br>subjects affected / exposed<br>occurrences (all)         | 1 / 13 (7.69%)<br>1 | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  |
| Blood and lymphatic system disorders                                   |                     |                     |                     |
| Anaemia<br>subjects affected / exposed<br>occurrences (all)            | 1 / 13 (7.69%)<br>2 | 0 / 3 (0.00%)<br>0  | 1 / 3 (33.33%)<br>1 |
| Blood loss anaemia<br>subjects affected / exposed<br>occurrences (all) | 0 / 13 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  |
| Leukocytosis<br>subjects affected / exposed<br>occurrences (all)       | 0 / 13 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  |
| Leukopenia<br>subjects affected / exposed<br>occurrences (all)         | 0 / 13 (0.00%)<br>0 | 1 / 3 (33.33%)<br>1 | 0 / 3 (0.00%)<br>0  |
| Lymph node pain<br>subjects affected / exposed<br>occurrences (all)    | 1 / 13 (7.69%)<br>1 | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  |
| Ear and labyrinth disorders                                            |                     |                     |                     |
| Ear congestion<br>subjects affected / exposed<br>occurrences (all)     | 1 / 13 (7.69%)<br>1 | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  |
| Tinnitus<br>subjects affected / exposed<br>occurrences (all)           | 1 / 13 (7.69%)<br>1 | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  |
| Vertigo<br>subjects affected / exposed<br>occurrences (all)            | 0 / 13 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  |
| Eye disorders                                                          |                     |                     |                     |
| Diplopia<br>subjects affected / exposed<br>occurrences (all)           | 0 / 13 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  |
| Eyelid ptosis                                                          |                     |                     |                     |

|                             |                 |               |                |
|-----------------------------|-----------------|---------------|----------------|
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 0               | 0             | 0              |
| Periorbital oedema          |                 |               |                |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 0               | 0             | 0              |
| Vision blurred              |                 |               |                |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 0               | 0             | 0              |
| Gastrointestinal disorders  |                 |               |                |
| Abdominal discomfort        |                 |               |                |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all)           | 0               | 0             | 1              |
| Abdominal distension        |                 |               |                |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 0               | 0             | 0              |
| Abdominal pain              |                 |               |                |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 3 (0.00%) | 1 / 3 (33.33%) |
| occurrences (all)           | 2               | 0             | 1              |
| Colitis                     |                 |               |                |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 0               | 0             | 0              |
| Constipation                |                 |               |                |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 0               | 0             | 0              |
| Dental caries               |                 |               |                |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 0               | 0             | 0              |
| Diarrhoea                   |                 |               |                |
| subjects affected / exposed | 2 / 13 (15.38%) | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 2               | 0             | 0              |
| Dyspepsia                   |                 |               |                |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 0               | 0             | 0              |
| Dysphagia                   |                 |               |                |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)           | 1               | 0             | 0              |

|                                        |                |               |                |
|----------------------------------------|----------------|---------------|----------------|
| Flatulence                             |                |               |                |
| subjects affected / exposed            | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)                      | 0              | 0             | 0              |
| Hiatus hernia                          |                |               |                |
| subjects affected / exposed            | 1 / 13 (7.69%) | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)                      | 1              | 0             | 0              |
| Hypoaesthesia oral                     |                |               |                |
| subjects affected / exposed            | 1 / 13 (7.69%) | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)                      | 1              | 0             | 0              |
| Inguinal hernia                        |                |               |                |
| subjects affected / exposed            | 1 / 13 (7.69%) | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)                      | 2              | 0             | 0              |
| Nausea                                 |                |               |                |
| subjects affected / exposed            | 1 / 13 (7.69%) | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)                      | 2              | 0             | 0              |
| Rectal tenesmus                        |                |               |                |
| subjects affected / exposed            | 1 / 13 (7.69%) | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)                      | 1              | 0             | 0              |
| Toothache                              |                |               |                |
| subjects affected / exposed            | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 2 / 3 (66.67%) |
| occurrences (all)                      | 0              | 0             | 2              |
| Vomiting                               |                |               |                |
| subjects affected / exposed            | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)                      | 0              | 0             | 0              |
| Skin and subcutaneous tissue disorders |                |               |                |
| Alopecia                               |                |               |                |
| subjects affected / exposed            | 1 / 13 (7.69%) | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)                      | 1              | 0             | 0              |
| Dry skin                               |                |               |                |
| subjects affected / exposed            | 1 / 13 (7.69%) | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)                      | 1              | 0             | 0              |
| Ecchymosis                             |                |               |                |
| subjects affected / exposed            | 1 / 13 (7.69%) | 0 / 3 (0.00%) | 0 / 3 (0.00%)  |
| occurrences (all)                      | 1              | 0             | 0              |
| Erythema                               |                |               |                |

|                             |                 |               |               |
|-----------------------------|-----------------|---------------|---------------|
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 0               | 0             | 0             |
| Hyperhidrosis               |                 |               |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 0               | 0             | 0             |
| Night sweats                |                 |               |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 0               | 0             | 0             |
| Pruritus                    |                 |               |               |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 1               | 0             | 0             |
| Rash                        |                 |               |               |
| subjects affected / exposed | 2 / 13 (15.38%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 3               | 0             | 0             |
| Rash papular                |                 |               |               |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 1               | 0             | 0             |
| Skin discolouration         |                 |               |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 0               | 0             | 0             |
| Skin hyperpigmentation      |                 |               |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 0               | 0             | 0             |
| Skin reaction               |                 |               |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 0               | 0             | 0             |
| Skin swelling               |                 |               |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 0               | 0             | 0             |
| Skin texture abnormal       |                 |               |               |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 1               | 0             | 0             |
| Renal and urinary disorders |                 |               |               |
| Dysuria                     |                 |               |               |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 1               | 0             | 0             |

|                                                                        |                      |                     |                     |
|------------------------------------------------------------------------|----------------------|---------------------|---------------------|
| Hydronephrosis<br>subjects affected / exposed<br>occurrences (all)     | 1 / 13 (7.69%)<br>1  | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  |
| Urinary hesitation<br>subjects affected / exposed<br>occurrences (all) | 0 / 13 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  |
| Endocrine disorders                                                    |                      |                     |                     |
| Hyperthyroidism<br>subjects affected / exposed<br>occurrences (all)    | 0 / 13 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  |
| Hypothyroidism<br>subjects affected / exposed<br>occurrences (all)     | 0 / 13 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  |
| Musculoskeletal and connective tissue disorders                        |                      |                     |                     |
| Arthralgia<br>subjects affected / exposed<br>occurrences (all)         | 0 / 13 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  |
| Back pain<br>subjects affected / exposed<br>occurrences (all)          | 2 / 13 (15.38%)<br>2 | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  |
| Bone pain<br>subjects affected / exposed<br>occurrences (all)          | 0 / 13 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  |
| Flank pain<br>subjects affected / exposed<br>occurrences (all)         | 1 / 13 (7.69%)<br>1  | 0 / 3 (0.00%)<br>0  | 1 / 3 (33.33%)<br>1 |
| Gouty arthritis<br>subjects affected / exposed<br>occurrences (all)    | 0 / 13 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  |
| Groin pain<br>subjects affected / exposed<br>occurrences (all)         | 0 / 13 (0.00%)<br>0  | 1 / 3 (33.33%)<br>1 | 0 / 3 (0.00%)<br>0  |
| Muscle spasms<br>subjects affected / exposed<br>occurrences (all)      | 0 / 13 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  | 0 / 3 (0.00%)<br>0  |
| Musculoskeletal chest pain                                             |                      |                     |                     |

|                             |                |               |               |
|-----------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 0              | 0             | 0             |
| Musculoskeletal pain        |                |               |               |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 0              | 0             | 0             |
| Myalgia                     |                |               |               |
| subjects affected / exposed | 1 / 13 (7.69%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 1              | 0             | 0             |
| Pain in extremity           |                |               |               |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 0              | 0             | 0             |
| Plantar fasciitis           |                |               |               |
| subjects affected / exposed | 1 / 13 (7.69%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 1              | 0             | 0             |
| Infections and infestations |                |               |               |
| Candida infection           |                |               |               |
| subjects affected / exposed | 1 / 13 (7.69%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 1              | 0             | 0             |
| Cellulitis                  |                |               |               |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 0              | 0             | 0             |
| Conjunctivitis              |                |               |               |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 0              | 0             | 0             |
| Diverticulitis              |                |               |               |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 0              | 0             | 0             |
| Helicobacter duodenitis     |                |               |               |
| subjects affected / exposed | 1 / 13 (7.69%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 1              | 0             | 0             |
| Herpes virus infection      |                |               |               |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 0              | 0             | 0             |
| Influenza                   |                |               |               |
| subjects affected / exposed | 1 / 13 (7.69%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 1              | 0             | 0             |

|                                    |                 |               |               |
|------------------------------------|-----------------|---------------|---------------|
| Nasopharyngitis                    |                 |               |               |
| subjects affected / exposed        | 1 / 13 (7.69%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                  | 1               | 0             | 0             |
| Oesophagitis bacterial             |                 |               |               |
| subjects affected / exposed        | 1 / 13 (7.69%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                  | 1               | 0             | 0             |
| Oral herpes                        |                 |               |               |
| subjects affected / exposed        | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                  | 0               | 0             | 0             |
| Rhinovirus infection               |                 |               |               |
| subjects affected / exposed        | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                  | 0               | 0             | 0             |
| Sinusitis                          |                 |               |               |
| subjects affected / exposed        | 2 / 13 (15.38%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                  | 3               | 0             | 0             |
| Tooth infection                    |                 |               |               |
| subjects affected / exposed        | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                  | 0               | 0             | 0             |
| Upper respiratory tract infection  |                 |               |               |
| subjects affected / exposed        | 2 / 13 (15.38%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                  | 5               | 0             | 0             |
| Urinary tract infection            |                 |               |               |
| subjects affected / exposed        | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                  | 0               | 0             | 0             |
| Metabolism and nutrition disorders |                 |               |               |
| Decreased appetite                 |                 |               |               |
| subjects affected / exposed        | 1 / 13 (7.69%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                  | 1               | 0             | 0             |
| Hyperglycaemia                     |                 |               |               |
| subjects affected / exposed        | 1 / 13 (7.69%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                  | 3               | 0             | 0             |
| Hyperkalaemia                      |                 |               |               |
| subjects affected / exposed        | 0 / 13 (0.00%)  | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)                  | 0               | 0             | 0             |
| Hyperlipidaemia                    |                 |               |               |

|                             |                |               |               |
|-----------------------------|----------------|---------------|---------------|
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 0              | 0             | 0             |
| Hypernatraemia              |                |               |               |
| subjects affected / exposed | 1 / 13 (7.69%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 1              | 0             | 0             |
| Hyperuricaemia              |                |               |               |
| subjects affected / exposed | 1 / 13 (7.69%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 2              | 0             | 0             |
| Hypoalbuminaemia            |                |               |               |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 0              | 0             | 0             |
| Hypocalcaemia               |                |               |               |
| subjects affected / exposed | 1 / 13 (7.69%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 1              | 0             | 0             |
| Hypokalaemia                |                |               |               |
| subjects affected / exposed | 0 / 13 (0.00%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 0              | 0             | 0             |
| Hyponatraemia               |                |               |               |
| subjects affected / exposed | 1 / 13 (7.69%) | 0 / 3 (0.00%) | 0 / 3 (0.00%) |
| occurrences (all)           | 1              | 0             | 0             |

| <b>Non-serious adverse events</b>                     | Part 2: Local Radiation + G100 10µg/lesion+Pembrolizumab 200mg | Part 2: Local Radiation, G100 20 µg/lesion in Large Tumors | Part 4: G100 20µg/lesion and pembrolizumab 200mg |
|-------------------------------------------------------|----------------------------------------------------------------|------------------------------------------------------------|--------------------------------------------------|
| Total subjects affected by non-serious adverse events |                                                                |                                                            |                                                  |
| subjects affected / exposed                           | 13 / 13 (100.00%)                                              | 4 / 4 (100.00%)                                            | 1 / 1 (100.00%)                                  |
| Vascular disorders                                    |                                                                |                                                            |                                                  |
| Diastolic hypertension                                |                                                                |                                                            |                                                  |
| subjects affected / exposed                           | 1 / 13 (7.69%)                                                 | 0 / 4 (0.00%)                                              | 0 / 1 (0.00%)                                    |
| occurrences (all)                                     | 1                                                              | 0                                                          | 0                                                |
| Embolism                                              |                                                                |                                                            |                                                  |
| subjects affected / exposed                           | 1 / 13 (7.69%)                                                 | 0 / 4 (0.00%)                                              | 0 / 1 (0.00%)                                    |
| occurrences (all)                                     | 1                                                              | 0                                                          | 0                                                |
| Flushing                                              |                                                                |                                                            |                                                  |
| subjects affected / exposed                           | 0 / 13 (0.00%)                                                 | 0 / 4 (0.00%)                                              | 0 / 1 (0.00%)                                    |
| occurrences (all)                                     | 0                                                              | 0                                                          | 0                                                |
| Haematoma                                             |                                                                |                                                            |                                                  |

|                                                      |                 |                |                 |
|------------------------------------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed                          | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)                                    | 1               | 0              | 0               |
| Hot flush                                            |                 |                |                 |
| subjects affected / exposed                          | 0 / 13 (0.00%)  | 1 / 4 (25.00%) | 0 / 1 (0.00%)   |
| occurrences (all)                                    | 0               | 1              | 0               |
| Hypertension                                         |                 |                |                 |
| subjects affected / exposed                          | 2 / 13 (15.38%) | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)                                    | 4               | 0              | 0               |
| Hypotension                                          |                 |                |                 |
| subjects affected / exposed                          | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)                                    | 1               | 0              | 0               |
| Systolic hypertension                                |                 |                |                 |
| subjects affected / exposed                          | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)                                    | 1               | 0              | 0               |
| Varicose vein                                        |                 |                |                 |
| subjects affected / exposed                          | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)                                    | 0               | 0              | 0               |
| General disorders and administration site conditions |                 |                |                 |
| Administration site pain                             |                 |                |                 |
| subjects affected / exposed                          | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)                                    | 1               | 0              | 0               |
| Asthenia                                             |                 |                |                 |
| subjects affected / exposed                          | 4 / 13 (30.77%) | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)                                    | 7               | 0              | 0               |
| Chest pain                                           |                 |                |                 |
| subjects affected / exposed                          | 2 / 13 (15.38%) | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)                                    | 2               | 0              | 0               |
| Chills                                               |                 |                |                 |
| subjects affected / exposed                          | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)                                    | 1               | 0              | 0               |
| Fatigue                                              |                 |                |                 |
| subjects affected / exposed                          | 4 / 13 (30.77%) | 2 / 4 (50.00%) | 1 / 1 (100.00%) |
| occurrences (all)                                    | 4               | 2              | 1               |
| Feeling hot                                          |                 |                |                 |

|                             |                 |               |               |
|-----------------------------|-----------------|---------------|---------------|
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 4 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all)           | 1               | 0             | 0             |
| Influenza like illness      |                 |               |               |
| subjects affected / exposed | 2 / 13 (15.38%) | 0 / 4 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all)           | 2               | 0             | 0             |
| Infusion site swelling      |                 |               |               |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 4 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all)           | 1               | 0             | 0             |
| Injection site bruising     |                 |               |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0             | 0             |
| Injection site discomfort   |                 |               |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0             | 0             |
| Injection site erythema     |                 |               |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0             | 0             |
| Injection site pain         |                 |               |               |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 4 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all)           | 1               | 0             | 0             |
| Injection site reaction     |                 |               |               |
| subjects affected / exposed | 2 / 13 (15.38%) | 0 / 4 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all)           | 4               | 0             | 0             |
| Injection site swelling     |                 |               |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0             | 0             |
| Oedema peripheral           |                 |               |               |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 4 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all)           | 1               | 0             | 0             |
| Pain                        |                 |               |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0             | 0             |
| Peripheral swelling         |                 |               |               |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 4 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all)           | 1               | 0             | 0             |
| Pyrexia                     |                 |               |               |

|                                                  |                     |                     |                    |
|--------------------------------------------------|---------------------|---------------------|--------------------|
| subjects affected / exposed<br>occurrences (all) | 1 / 13 (7.69%)<br>1 | 1 / 4 (25.00%)<br>4 | 0 / 1 (0.00%)<br>0 |
| Immune system disorders                          |                     |                     |                    |
| Drug hypersensitivity                            |                     |                     |                    |
| subjects affected / exposed                      | 0 / 13 (0.00%)      | 0 / 4 (0.00%)       | 0 / 1 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Seasonal allergy                                 |                     |                     |                    |
| subjects affected / exposed                      | 1 / 13 (7.69%)      | 0 / 4 (0.00%)       | 0 / 1 (0.00%)      |
| occurrences (all)                                | 1                   | 0                   | 0                  |
| Reproductive system and breast disorders         |                     |                     |                    |
| Epididymal cyst                                  |                     |                     |                    |
| subjects affected / exposed                      | 1 / 13 (7.69%)      | 0 / 4 (0.00%)       | 0 / 1 (0.00%)      |
| occurrences (all)                                | 1                   | 0                   | 0                  |
| Oedema genital                                   |                     |                     |                    |
| subjects affected / exposed                      | 0 / 13 (0.00%)      | 0 / 4 (0.00%)       | 0 / 1 (0.00%)      |
| occurrences (all)                                | 0                   | 0                   | 0                  |
| Testicular atrophy                               |                     |                     |                    |
| subjects affected / exposed                      | 1 / 13 (7.69%)      | 0 / 4 (0.00%)       | 0 / 1 (0.00%)      |
| occurrences (all)                                | 1                   | 0                   | 0                  |
| Testis discomfort                                |                     |                     |                    |
| subjects affected / exposed                      | 1 / 13 (7.69%)      | 0 / 4 (0.00%)       | 0 / 1 (0.00%)      |
| occurrences (all)                                | 1                   | 0                   | 0                  |
| Vulvovaginal inflammation                        |                     |                     |                    |
| subjects affected / exposed                      | 1 / 13 (7.69%)      | 0 / 4 (0.00%)       | 0 / 1 (0.00%)      |
| occurrences (all)                                | 1                   | 0                   | 0                  |
| Respiratory, thoracic and mediastinal disorders  |                     |                     |                    |
| Asthma                                           |                     |                     |                    |
| subjects affected / exposed                      | 1 / 13 (7.69%)      | 0 / 4 (0.00%)       | 0 / 1 (0.00%)      |
| occurrences (all)                                | 1                   | 0                   | 0                  |
| Cough                                            |                     |                     |                    |
| subjects affected / exposed                      | 4 / 13 (30.77%)     | 0 / 4 (0.00%)       | 0 / 1 (0.00%)      |
| occurrences (all)                                | 5                   | 0                   | 0                  |
| Dyspnoea                                         |                     |                     |                    |
| subjects affected / exposed                      | 1 / 13 (7.69%)      | 0 / 4 (0.00%)       | 0 / 1 (0.00%)      |
| occurrences (all)                                | 1                   | 0                   | 0                  |
| Nasal congestion                                 |                     |                     |                    |

|                             |                 |                |                 |
|-----------------------------|-----------------|----------------|-----------------|
| subjects affected / exposed | 2 / 13 (15.38%) | 0 / 4 (0.00%)  | 1 / 1 (100.00%) |
| occurrences (all)           | 4               | 0              | 1               |
| Oropharyngeal pain          |                 |                |                 |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)           | 0               | 0              | 0               |
| Pleural effusion            |                 |                |                 |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)           | 0               | 0              | 0               |
| Productive cough            |                 |                |                 |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)           | 1               | 0              | 0               |
| Pulmonary congestion        |                 |                |                 |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)           | 1               | 0              | 0               |
| Sinus congestion            |                 |                |                 |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)           | 0               | 0              | 0               |
| Throat irritation           |                 |                |                 |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)           | 0               | 0              | 0               |
| Upper-airway cough syndrome |                 |                |                 |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)           | 3               | 0              | 0               |
| Psychiatric disorders       |                 |                |                 |
| Depression                  |                 |                |                 |
| subjects affected / exposed | 1 / 13 (7.69%)  | 1 / 4 (25.00%) | 0 / 1 (0.00%)   |
| occurrences (all)           | 1               | 1              | 0               |
| Insomnia                    |                 |                |                 |
| subjects affected / exposed | 0 / 13 (0.00%)  | 1 / 4 (25.00%) | 0 / 1 (0.00%)   |
| occurrences (all)           | 0               | 1              | 0               |
| Libido decreased            |                 |                |                 |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)           | 1               | 0              | 0               |
| Restlessness                |                 |                |                 |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)           | 0               | 0              | 0               |

|                                                                                          |                      |                     |                    |
|------------------------------------------------------------------------------------------|----------------------|---------------------|--------------------|
| Sleep disorder<br>subjects affected / exposed<br>occurrences (all)                       | 1 / 13 (7.69%)<br>1  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Investigations                                                                           |                      |                     |                    |
| Alanine aminotransferase increased<br>subjects affected / exposed<br>occurrences (all)   | 3 / 13 (23.08%)<br>5 | 1 / 4 (25.00%)<br>1 | 0 / 1 (0.00%)<br>0 |
| Aspartate aminotransferase increased<br>subjects affected / exposed<br>occurrences (all) | 2 / 13 (15.38%)<br>2 | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Blast cell count increased<br>subjects affected / exposed<br>occurrences (all)           | 0 / 13 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Blood alkaline phosphatase increased<br>subjects affected / exposed<br>occurrences (all) | 2 / 13 (15.38%)<br>5 | 1 / 4 (25.00%)<br>2 | 0 / 1 (0.00%)<br>0 |
| Blood bilirubin decreased<br>subjects affected / exposed<br>occurrences (all)            | 1 / 13 (7.69%)<br>1  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Blood bilirubin increased<br>subjects affected / exposed<br>occurrences (all)            | 0 / 13 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Blood creatinine decreased<br>subjects affected / exposed<br>occurrences (all)           | 1 / 13 (7.69%)<br>1  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Blood creatinine increased<br>subjects affected / exposed<br>occurrences (all)           | 0 / 13 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Blood glucose increased<br>subjects affected / exposed<br>occurrences (all)              | 0 / 13 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Breath sounds abnormal<br>subjects affected / exposed<br>occurrences (all)               | 0 / 13 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Haemoglobin increased                                                                    |                      |                     |                    |

|                                                |                 |                |               |
|------------------------------------------------|-----------------|----------------|---------------|
| subjects affected / exposed                    | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)                              | 1               | 0              | 0             |
| Lymphocyte count decreased                     |                 |                |               |
| subjects affected / exposed                    | 0 / 13 (0.00%)  | 1 / 4 (25.00%) | 0 / 1 (0.00%) |
| occurrences (all)                              | 0               | 1              | 0             |
| Neutrophil count decreased                     |                 |                |               |
| subjects affected / exposed                    | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)                              | 0               | 0              | 0             |
| Platelet count decreased                       |                 |                |               |
| subjects affected / exposed                    | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)                              | 0               | 0              | 0             |
| White blood cell count decreased               |                 |                |               |
| subjects affected / exposed                    | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)                              | 1               | 0              | 0             |
| Injury, poisoning and procedural complications |                 |                |               |
| Contusion                                      |                 |                |               |
| subjects affected / exposed                    | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)                              | 3               | 0              | 0             |
| Expired product administered                   |                 |                |               |
| subjects affected / exposed                    | 2 / 13 (15.38%) | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)                              | 3               | 0              | 0             |
| Fall                                           |                 |                |               |
| subjects affected / exposed                    | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)                              | 1               | 0              | 0             |
| Procedural pain                                |                 |                |               |
| subjects affected / exposed                    | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)                              | 2               | 0              | 0             |
| Radiation associated pain                      |                 |                |               |
| subjects affected / exposed                    | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)                              | 0               | 0              | 0             |
| Radiation skin injury                          |                 |                |               |
| subjects affected / exposed                    | 0 / 13 (0.00%)  | 1 / 4 (25.00%) | 0 / 1 (0.00%) |
| occurrences (all)                              | 0               | 1              | 0             |
| Skin laceration                                |                 |                |               |

|                                                  |                     |                    |                    |
|--------------------------------------------------|---------------------|--------------------|--------------------|
| subjects affected / exposed<br>occurrences (all) | 1 / 13 (7.69%)<br>1 | 0 / 4 (0.00%)<br>0 | 0 / 1 (0.00%)<br>0 |
| Cardiac disorders                                |                     |                    |                    |
| Coronary artery disease                          |                     |                    |                    |
| subjects affected / exposed                      | 0 / 13 (0.00%)      | 0 / 4 (0.00%)      | 0 / 1 (0.00%)      |
| occurrences (all)                                | 0                   | 0                  | 0                  |
| Myocardial fibrosis                              |                     |                    |                    |
| subjects affected / exposed                      | 0 / 13 (0.00%)      | 0 / 4 (0.00%)      | 0 / 1 (0.00%)      |
| occurrences (all)                                | 0                   | 0                  | 0                  |
| Sinus bradycardia                                |                     |                    |                    |
| subjects affected / exposed                      | 0 / 13 (0.00%)      | 0 / 4 (0.00%)      | 0 / 1 (0.00%)      |
| occurrences (all)                                | 0                   | 0                  | 0                  |
| Tachycardia                                      |                     |                    |                    |
| subjects affected / exposed                      | 1 / 13 (7.69%)      | 0 / 4 (0.00%)      | 0 / 1 (0.00%)      |
| occurrences (all)                                | 1                   | 0                  | 0                  |
| Nervous system disorders                         |                     |                    |                    |
| Carpal tunnel syndrome                           |                     |                    |                    |
| subjects affected / exposed                      | 1 / 13 (7.69%)      | 0 / 4 (0.00%)      | 0 / 1 (0.00%)      |
| occurrences (all)                                | 1                   | 0                  | 0                  |
| Dizziness                                        |                     |                    |                    |
| subjects affected / exposed                      | 2 / 13 (15.38%)     | 0 / 4 (0.00%)      | 0 / 1 (0.00%)      |
| occurrences (all)                                | 3                   | 0                  | 0                  |
| Dysgeusia                                        |                     |                    |                    |
| subjects affected / exposed                      | 0 / 13 (0.00%)      | 0 / 4 (0.00%)      | 0 / 1 (0.00%)      |
| occurrences (all)                                | 0                   | 0                  | 0                  |
| Headache                                         |                     |                    |                    |
| subjects affected / exposed                      | 1 / 13 (7.69%)      | 0 / 4 (0.00%)      | 0 / 1 (0.00%)      |
| occurrences (all)                                | 1                   | 0                  | 0                  |
| Neuropathy peripheral                            |                     |                    |                    |
| subjects affected / exposed                      | 0 / 13 (0.00%)      | 0 / 4 (0.00%)      | 0 / 1 (0.00%)      |
| occurrences (all)                                | 0                   | 0                  | 0                  |
| Nystagmus                                        |                     |                    |                    |
| subjects affected / exposed                      | 0 / 13 (0.00%)      | 0 / 4 (0.00%)      | 0 / 1 (0.00%)      |
| occurrences (all)                                | 0                   | 0                  | 0                  |
| Presyncope                                       |                     |                    |                    |

|                                                  |                     |                    |                    |
|--------------------------------------------------|---------------------|--------------------|--------------------|
| subjects affected / exposed<br>occurrences (all) | 0 / 13 (0.00%)<br>0 | 0 / 4 (0.00%)<br>0 | 0 / 1 (0.00%)<br>0 |
| Blood and lymphatic system disorders             |                     |                    |                    |
| Anaemia                                          |                     |                    |                    |
| subjects affected / exposed                      | 2 / 13 (15.38%)     | 1 / 4 (25.00%)     | 0 / 1 (0.00%)      |
| occurrences (all)                                | 3                   | 4                  | 0                  |
| Blood loss anaemia                               |                     |                    |                    |
| subjects affected / exposed                      | 1 / 13 (7.69%)      | 0 / 4 (0.00%)      | 0 / 1 (0.00%)      |
| occurrences (all)                                | 1                   | 0                  | 0                  |
| Leukocytosis                                     |                     |                    |                    |
| subjects affected / exposed                      | 0 / 13 (0.00%)      | 0 / 4 (0.00%)      | 0 / 1 (0.00%)      |
| occurrences (all)                                | 0                   | 0                  | 0                  |
| Leukopenia                                       |                     |                    |                    |
| subjects affected / exposed                      | 0 / 13 (0.00%)      | 0 / 4 (0.00%)      | 0 / 1 (0.00%)      |
| occurrences (all)                                | 0                   | 0                  | 0                  |
| Lymph node pain                                  |                     |                    |                    |
| subjects affected / exposed                      | 1 / 13 (7.69%)      | 0 / 4 (0.00%)      | 0 / 1 (0.00%)      |
| occurrences (all)                                | 1                   | 0                  | 0                  |
| Ear and labyrinth disorders                      |                     |                    |                    |
| Ear congestion                                   |                     |                    |                    |
| subjects affected / exposed                      | 0 / 13 (0.00%)      | 0 / 4 (0.00%)      | 0 / 1 (0.00%)      |
| occurrences (all)                                | 0                   | 0                  | 0                  |
| Tinnitus                                         |                     |                    |                    |
| subjects affected / exposed                      | 0 / 13 (0.00%)      | 0 / 4 (0.00%)      | 0 / 1 (0.00%)      |
| occurrences (all)                                | 0                   | 0                  | 0                  |
| Vertigo                                          |                     |                    |                    |
| subjects affected / exposed                      | 0 / 13 (0.00%)      | 1 / 4 (25.00%)     | 0 / 1 (0.00%)      |
| occurrences (all)                                | 0                   | 1                  | 0                  |
| Eye disorders                                    |                     |                    |                    |
| Diplopia                                         |                     |                    |                    |
| subjects affected / exposed                      | 0 / 13 (0.00%)      | 0 / 4 (0.00%)      | 0 / 1 (0.00%)      |
| occurrences (all)                                | 0                   | 0                  | 0                  |
| Eyelid ptosis                                    |                     |                    |                    |
| subjects affected / exposed                      | 0 / 13 (0.00%)      | 0 / 4 (0.00%)      | 0 / 1 (0.00%)      |
| occurrences (all)                                | 0                   | 0                  | 0                  |
| Periorbital oedema                               |                     |                    |                    |

|                             |                 |                |               |
|-----------------------------|-----------------|----------------|---------------|
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0              | 0             |
| Vision blurred              |                 |                |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0              | 0             |
| Gastrointestinal disorders  |                 |                |               |
| Abdominal discomfort        |                 |                |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0              | 0             |
| Abdominal distension        |                 |                |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 1 / 4 (25.00%) | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 1              | 0             |
| Abdominal pain              |                 |                |               |
| subjects affected / exposed | 2 / 13 (15.38%) | 2 / 4 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all)           | 4               | 3              | 0             |
| Colitis                     |                 |                |               |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 2               | 0              | 0             |
| Constipation                |                 |                |               |
| subjects affected / exposed | 2 / 13 (15.38%) | 1 / 4 (25.00%) | 0 / 1 (0.00%) |
| occurrences (all)           | 2               | 2              | 0             |
| Dental caries               |                 |                |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0              | 0             |
| Diarrhoea                   |                 |                |               |
| subjects affected / exposed | 4 / 13 (30.77%) | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 4               | 0              | 0             |
| Dyspepsia                   |                 |                |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 1 / 4 (25.00%) | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 1              | 0             |
| Dysphagia                   |                 |                |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0              | 0             |
| Flatulence                  |                 |                |               |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 1               | 0              | 0             |

|                                        |                 |                |                 |
|----------------------------------------|-----------------|----------------|-----------------|
| Hiatus hernia                          |                 |                |                 |
| subjects affected / exposed            | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)                      | 0               | 0              | 0               |
| Hypoaesthesia oral                     |                 |                |                 |
| subjects affected / exposed            | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)                      | 0               | 0              | 0               |
| Inguinal hernia                        |                 |                |                 |
| subjects affected / exposed            | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)                      | 0               | 0              | 0               |
| Nausea                                 |                 |                |                 |
| subjects affected / exposed            | 6 / 13 (46.15%) | 1 / 4 (25.00%) | 0 / 1 (0.00%)   |
| occurrences (all)                      | 7               | 2              | 0               |
| Rectal tenesmus                        |                 |                |                 |
| subjects affected / exposed            | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)                      | 0               | 0              | 0               |
| Toothache                              |                 |                |                 |
| subjects affected / exposed            | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)                      | 0               | 0              | 0               |
| Vomiting                               |                 |                |                 |
| subjects affected / exposed            | 3 / 13 (23.08%) | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)                      | 3               | 0              | 0               |
| Skin and subcutaneous tissue disorders |                 |                |                 |
| Alopecia                               |                 |                |                 |
| subjects affected / exposed            | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)                      | 0               | 0              | 0               |
| Dry skin                               |                 |                |                 |
| subjects affected / exposed            | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)                      | 1               | 0              | 0               |
| Ecchymosis                             |                 |                |                 |
| subjects affected / exposed            | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 1 / 1 (100.00%) |
| occurrences (all)                      | 0               | 0              | 1               |
| Erythema                               |                 |                |                 |
| subjects affected / exposed            | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%)   |
| occurrences (all)                      | 2               | 0              | 0               |
| Hyperhidrosis                          |                 |                |                 |

|                             |                 |                |               |
|-----------------------------|-----------------|----------------|---------------|
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0              | 0             |
| Night sweats                |                 |                |               |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 1               | 0              | 0             |
| Pruritus                    |                 |                |               |
| subjects affected / exposed | 1 / 13 (7.69%)  | 1 / 4 (25.00%) | 0 / 1 (0.00%) |
| occurrences (all)           | 1               | 1              | 0             |
| Rash                        |                 |                |               |
| subjects affected / exposed | 3 / 13 (23.08%) | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 5               | 0              | 0             |
| Rash papular                |                 |                |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0              | 0             |
| Skin discolouration         |                 |                |               |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 1               | 0              | 0             |
| Skin hyperpigmentation      |                 |                |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0              | 0             |
| Skin reaction               |                 |                |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0              | 0             |
| Skin swelling               |                 |                |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0              | 0             |
| Skin texture abnormal       |                 |                |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0              | 0             |
| Renal and urinary disorders |                 |                |               |
| Dysuria                     |                 |                |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0              | 0             |
| Hydronephrosis              |                 |                |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0              | 0             |

|                                                                                |                      |                     |                    |
|--------------------------------------------------------------------------------|----------------------|---------------------|--------------------|
| Urinary hesitation<br>subjects affected / exposed<br>occurrences (all)         | 1 / 13 (7.69%)<br>1  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Endocrine disorders                                                            |                      |                     |                    |
| Hyperthyroidism<br>subjects affected / exposed<br>occurrences (all)            | 1 / 13 (7.69%)<br>1  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Hypothyroidism<br>subjects affected / exposed<br>occurrences (all)             | 1 / 13 (7.69%)<br>2  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Musculoskeletal and connective tissue disorders                                |                      |                     |                    |
| Arthralgia<br>subjects affected / exposed<br>occurrences (all)                 | 3 / 13 (23.08%)<br>3 | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Back pain<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 13 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Bone pain<br>subjects affected / exposed<br>occurrences (all)                  | 1 / 13 (7.69%)<br>1  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Flank pain<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 13 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Gouty arthritis<br>subjects affected / exposed<br>occurrences (all)            | 0 / 13 (0.00%)<br>0  | 1 / 4 (25.00%)<br>1 | 0 / 1 (0.00%)<br>0 |
| Groin pain<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 13 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Muscle spasms<br>subjects affected / exposed<br>occurrences (all)              | 0 / 13 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Musculoskeletal chest pain<br>subjects affected / exposed<br>occurrences (all) | 2 / 13 (15.38%)<br>2 | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Musculoskeletal pain                                                           |                      |                     |                    |

|                             |                 |                |               |
|-----------------------------|-----------------|----------------|---------------|
| subjects affected / exposed | 2 / 13 (15.38%) | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 2               | 0              | 0             |
| Myalgia                     |                 |                |               |
| subjects affected / exposed | 2 / 13 (15.38%) | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 2               | 0              | 0             |
| Pain in extremity           |                 |                |               |
| subjects affected / exposed | 1 / 13 (7.69%)  | 2 / 4 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all)           | 2               | 2              | 0             |
| Plantar fasciitis           |                 |                |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0              | 0             |
| Infections and infestations |                 |                |               |
| Candida infection           |                 |                |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0              | 0             |
| Cellulitis                  |                 |                |               |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 1               | 0              | 0             |
| Conjunctivitis              |                 |                |               |
| subjects affected / exposed | 2 / 13 (15.38%) | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 2               | 0              | 0             |
| Diverticulitis              |                 |                |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 1 / 4 (25.00%) | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 1              | 0             |
| Helicobacter duodenitis     |                 |                |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0              | 0             |
| Herpes virus infection      |                 |                |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0              | 0             |
| Influenza                   |                 |                |               |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 1               | 0              | 0             |
| Nasopharyngitis             |                 |                |               |
| subjects affected / exposed | 2 / 13 (15.38%) | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 3               | 0              | 0             |

|                                                                                       |                      |                     |                    |
|---------------------------------------------------------------------------------------|----------------------|---------------------|--------------------|
| Oesophagitis bacterial<br>subjects affected / exposed<br>occurrences (all)            | 0 / 13 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Oral herpes<br>subjects affected / exposed<br>occurrences (all)                       | 0 / 13 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Rhinovirus infection<br>subjects affected / exposed<br>occurrences (all)              | 1 / 13 (7.69%)<br>1  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Sinusitis<br>subjects affected / exposed<br>occurrences (all)                         | 0 / 13 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Tooth infection<br>subjects affected / exposed<br>occurrences (all)                   | 0 / 13 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Upper respiratory tract infection<br>subjects affected / exposed<br>occurrences (all) | 2 / 13 (15.38%)<br>2 | 1 / 4 (25.00%)<br>1 | 0 / 1 (0.00%)<br>0 |
| Urinary tract infection<br>subjects affected / exposed<br>occurrences (all)           | 0 / 13 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Metabolism and nutrition disorders                                                    |                      |                     |                    |
| Decreased appetite<br>subjects affected / exposed<br>occurrences (all)                | 0 / 13 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Hyperglycaemia<br>subjects affected / exposed<br>occurrences (all)                    | 3 / 13 (23.08%)<br>5 | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Hyperkalaemia<br>subjects affected / exposed<br>occurrences (all)                     | 0 / 13 (0.00%)<br>0  | 1 / 4 (25.00%)<br>7 | 0 / 1 (0.00%)<br>0 |
| Hyperlipidaemia<br>subjects affected / exposed<br>occurrences (all)                   | 0 / 13 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 0 / 1 (0.00%)<br>0 |
| Hypernatraemia                                                                        |                      |                     |                    |

|                             |                 |                |               |
|-----------------------------|-----------------|----------------|---------------|
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0              | 0             |
| Hyperuricaemia              |                 |                |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 0              | 0             |
| Hypoalbuminaemia            |                 |                |               |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 1               | 0              | 0             |
| Hypocalcaemia               |                 |                |               |
| subjects affected / exposed | 1 / 13 (7.69%)  | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 1               | 0              | 0             |
| Hypokalaemia                |                 |                |               |
| subjects affected / exposed | 0 / 13 (0.00%)  | 1 / 4 (25.00%) | 0 / 1 (0.00%) |
| occurrences (all)           | 0               | 1              | 0             |
| Hyponatraemia               |                 |                |               |
| subjects affected / exposed | 2 / 13 (15.38%) | 0 / 4 (0.00%)  | 0 / 1 (0.00%) |
| occurrences (all)           | 3               | 0              | 0             |

|                                                          |                                                  |  |  |
|----------------------------------------------------------|--------------------------------------------------|--|--|
| <b>Non-serious adverse events</b>                        | Part 3: Local<br>Radiation + G100<br>20µg/lesion |  |  |
| Total subjects affected by non-serious<br>adverse events |                                                  |  |  |
| subjects affected / exposed                              | 14 / 14 (100.00%)                                |  |  |
| Vascular disorders                                       |                                                  |  |  |
| Diastolic hypertension                                   |                                                  |  |  |
| subjects affected / exposed                              | 0 / 14 (0.00%)                                   |  |  |
| occurrences (all)                                        | 0                                                |  |  |
| Embolism                                                 |                                                  |  |  |
| subjects affected / exposed                              | 0 / 14 (0.00%)                                   |  |  |
| occurrences (all)                                        | 0                                                |  |  |
| Flushing                                                 |                                                  |  |  |
| subjects affected / exposed                              | 0 / 14 (0.00%)                                   |  |  |
| occurrences (all)                                        | 0                                                |  |  |
| Haematoma                                                |                                                  |  |  |
| subjects affected / exposed                              | 0 / 14 (0.00%)                                   |  |  |
| occurrences (all)                                        | 0                                                |  |  |
| Hot flush                                                |                                                  |  |  |

|                                                      |                 |  |  |
|------------------------------------------------------|-----------------|--|--|
| subjects affected / exposed                          | 0 / 14 (0.00%)  |  |  |
| occurrences (all)                                    | 0               |  |  |
| Hypertension                                         |                 |  |  |
| subjects affected / exposed                          | 1 / 14 (7.14%)  |  |  |
| occurrences (all)                                    | 1               |  |  |
| Hypotension                                          |                 |  |  |
| subjects affected / exposed                          | 0 / 14 (0.00%)  |  |  |
| occurrences (all)                                    | 0               |  |  |
| Systolic hypertension                                |                 |  |  |
| subjects affected / exposed                          | 0 / 14 (0.00%)  |  |  |
| occurrences (all)                                    | 0               |  |  |
| Varicose vein                                        |                 |  |  |
| subjects affected / exposed                          | 1 / 14 (7.14%)  |  |  |
| occurrences (all)                                    | 1               |  |  |
| General disorders and administration site conditions |                 |  |  |
| Administration site pain                             |                 |  |  |
| subjects affected / exposed                          | 0 / 14 (0.00%)  |  |  |
| occurrences (all)                                    | 0               |  |  |
| Asthenia                                             |                 |  |  |
| subjects affected / exposed                          | 0 / 14 (0.00%)  |  |  |
| occurrences (all)                                    | 0               |  |  |
| Chest pain                                           |                 |  |  |
| subjects affected / exposed                          | 0 / 14 (0.00%)  |  |  |
| occurrences (all)                                    | 0               |  |  |
| Chills                                               |                 |  |  |
| subjects affected / exposed                          | 3 / 14 (21.43%) |  |  |
| occurrences (all)                                    | 3               |  |  |
| Fatigue                                              |                 |  |  |
| subjects affected / exposed                          | 3 / 14 (21.43%) |  |  |
| occurrences (all)                                    | 3               |  |  |
| Feeling hot                                          |                 |  |  |
| subjects affected / exposed                          | 0 / 14 (0.00%)  |  |  |
| occurrences (all)                                    | 0               |  |  |
| Influenza like illness                               |                 |  |  |

|                             |                 |  |  |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 2 / 14 (14.29%) |  |  |
| occurrences (all)           | 2               |  |  |
| Infusion site swelling      |                 |  |  |
| subjects affected / exposed | 0 / 14 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Injection site bruising     |                 |  |  |
| subjects affected / exposed | 1 / 14 (7.14%)  |  |  |
| occurrences (all)           | 1               |  |  |
| Injection site discomfort   |                 |  |  |
| subjects affected / exposed | 0 / 14 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Injection site erythema     |                 |  |  |
| subjects affected / exposed | 2 / 14 (14.29%) |  |  |
| occurrences (all)           | 2               |  |  |
| Injection site pain         |                 |  |  |
| subjects affected / exposed | 2 / 14 (14.29%) |  |  |
| occurrences (all)           | 3               |  |  |
| Injection site reaction     |                 |  |  |
| subjects affected / exposed | 1 / 14 (7.14%)  |  |  |
| occurrences (all)           | 8               |  |  |
| Injection site swelling     |                 |  |  |
| subjects affected / exposed | 0 / 14 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Oedema peripheral           |                 |  |  |
| subjects affected / exposed | 0 / 14 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Pain                        |                 |  |  |
| subjects affected / exposed | 3 / 14 (21.43%) |  |  |
| occurrences (all)           | 3               |  |  |
| Peripheral swelling         |                 |  |  |
| subjects affected / exposed | 1 / 14 (7.14%)  |  |  |
| occurrences (all)           | 1               |  |  |
| Pyrexia                     |                 |  |  |
| subjects affected / exposed | 2 / 14 (14.29%) |  |  |
| occurrences (all)           | 2               |  |  |
| Immune system disorders     |                 |  |  |

|                                                                               |                     |  |  |
|-------------------------------------------------------------------------------|---------------------|--|--|
| Drug hypersensitivity<br>subjects affected / exposed<br>occurrences (all)     | 1 / 14 (7.14%)<br>1 |  |  |
| Seasonal allergy<br>subjects affected / exposed<br>occurrences (all)          | 0 / 14 (0.00%)<br>0 |  |  |
| Reproductive system and breast disorders                                      |                     |  |  |
| Epididymal cyst<br>subjects affected / exposed<br>occurrences (all)           | 0 / 14 (0.00%)<br>0 |  |  |
| Oedema genital<br>subjects affected / exposed<br>occurrences (all)            | 0 / 14 (0.00%)<br>0 |  |  |
| Testicular atrophy<br>subjects affected / exposed<br>occurrences (all)        | 0 / 14 (0.00%)<br>0 |  |  |
| Testis discomfort<br>subjects affected / exposed<br>occurrences (all)         | 0 / 14 (0.00%)<br>0 |  |  |
| Vulvovaginal inflammation<br>subjects affected / exposed<br>occurrences (all) | 0 / 14 (0.00%)<br>0 |  |  |
| Respiratory, thoracic and mediastinal disorders                               |                     |  |  |
| Asthma<br>subjects affected / exposed<br>occurrences (all)                    | 0 / 14 (0.00%)<br>0 |  |  |
| Cough<br>subjects affected / exposed<br>occurrences (all)                     | 1 / 14 (7.14%)<br>1 |  |  |
| Dyspnoea<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 14 (0.00%)<br>0 |  |  |
| Nasal congestion<br>subjects affected / exposed<br>occurrences (all)          | 1 / 14 (7.14%)<br>1 |  |  |
| Oropharyngeal pain                                                            |                     |  |  |

|                             |                |  |  |
|-----------------------------|----------------|--|--|
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Pleural effusion            |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Productive cough            |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Pulmonary congestion        |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Sinus congestion            |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Throat irritation           |                |  |  |
| subjects affected / exposed | 1 / 14 (7.14%) |  |  |
| occurrences (all)           | 1              |  |  |
| Upper-airway cough syndrome |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Psychiatric disorders       |                |  |  |
| Depression                  |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Insomnia                    |                |  |  |
| subjects affected / exposed | 1 / 14 (7.14%) |  |  |
| occurrences (all)           | 1              |  |  |
| Libido decreased            |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Restlessness                |                |  |  |
| subjects affected / exposed | 1 / 14 (7.14%) |  |  |
| occurrences (all)           | 1              |  |  |
| Sleep disorder              |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |

|                                      |                 |  |  |
|--------------------------------------|-----------------|--|--|
| Investigations                       |                 |  |  |
| Alanine aminotransferase increased   |                 |  |  |
| subjects affected / exposed          | 0 / 14 (0.00%)  |  |  |
| occurrences (all)                    | 0               |  |  |
| Aspartate aminotransferase increased |                 |  |  |
| subjects affected / exposed          | 0 / 14 (0.00%)  |  |  |
| occurrences (all)                    | 0               |  |  |
| Blast cell count increased           |                 |  |  |
| subjects affected / exposed          | 0 / 14 (0.00%)  |  |  |
| occurrences (all)                    | 0               |  |  |
| Blood alkaline phosphatase increased |                 |  |  |
| subjects affected / exposed          | 0 / 14 (0.00%)  |  |  |
| occurrences (all)                    | 0               |  |  |
| Blood bilirubin decreased            |                 |  |  |
| subjects affected / exposed          | 0 / 14 (0.00%)  |  |  |
| occurrences (all)                    | 0               |  |  |
| Blood bilirubin increased            |                 |  |  |
| subjects affected / exposed          | 1 / 14 (7.14%)  |  |  |
| occurrences (all)                    | 5               |  |  |
| Blood creatinine decreased           |                 |  |  |
| subjects affected / exposed          | 0 / 14 (0.00%)  |  |  |
| occurrences (all)                    | 0               |  |  |
| Blood creatinine increased           |                 |  |  |
| subjects affected / exposed          | 2 / 14 (14.29%) |  |  |
| occurrences (all)                    | 3               |  |  |
| Blood glucose increased              |                 |  |  |
| subjects affected / exposed          | 1 / 14 (7.14%)  |  |  |
| occurrences (all)                    | 1               |  |  |
| Breath sounds abnormal               |                 |  |  |
| subjects affected / exposed          | 0 / 14 (0.00%)  |  |  |
| occurrences (all)                    | 0               |  |  |
| Haemoglobin increased                |                 |  |  |
| subjects affected / exposed          | 1 / 14 (7.14%)  |  |  |
| occurrences (all)                    | 1               |  |  |
| Lymphocyte count decreased           |                 |  |  |

|                                                                                      |                      |  |  |
|--------------------------------------------------------------------------------------|----------------------|--|--|
| subjects affected / exposed<br>occurrences (all)                                     | 3 / 14 (21.43%)<br>6 |  |  |
| Neutrophil count decreased<br>subjects affected / exposed<br>occurrences (all)       | 1 / 14 (7.14%)<br>2  |  |  |
| Platelet count decreased<br>subjects affected / exposed<br>occurrences (all)         | 1 / 14 (7.14%)<br>1  |  |  |
| White blood cell count decreased<br>subjects affected / exposed<br>occurrences (all) | 1 / 14 (7.14%)<br>1  |  |  |
| Injury, poisoning and procedural complications                                       |                      |  |  |
| Contusion<br>subjects affected / exposed<br>occurrences (all)                        | 0 / 14 (0.00%)<br>0  |  |  |
| Expired product administered<br>subjects affected / exposed<br>occurrences (all)     | 0 / 14 (0.00%)<br>0  |  |  |
| Fall<br>subjects affected / exposed<br>occurrences (all)                             | 0 / 14 (0.00%)<br>0  |  |  |
| Procedural pain<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 14 (0.00%)<br>0  |  |  |
| Radiation associated pain<br>subjects affected / exposed<br>occurrences (all)        | 1 / 14 (7.14%)<br>1  |  |  |
| Radiation skin injury<br>subjects affected / exposed<br>occurrences (all)            | 0 / 14 (0.00%)<br>0  |  |  |
| Skin laceration<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 14 (0.00%)<br>0  |  |  |
| Cardiac disorders                                                                    |                      |  |  |

|                                                                             |                      |  |  |
|-----------------------------------------------------------------------------|----------------------|--|--|
| Coronary artery disease<br>subjects affected / exposed<br>occurrences (all) | 0 / 14 (0.00%)<br>0  |  |  |
| Myocardial fibrosis<br>subjects affected / exposed<br>occurrences (all)     | 0 / 14 (0.00%)<br>0  |  |  |
| Sinus bradycardia<br>subjects affected / exposed<br>occurrences (all)       | 1 / 14 (7.14%)<br>1  |  |  |
| Tachycardia<br>subjects affected / exposed<br>occurrences (all)             | 1 / 14 (7.14%)<br>1  |  |  |
| Nervous system disorders                                                    |                      |  |  |
| Carpal tunnel syndrome<br>subjects affected / exposed<br>occurrences (all)  | 0 / 14 (0.00%)<br>0  |  |  |
| Dizziness<br>subjects affected / exposed<br>occurrences (all)               | 2 / 14 (14.29%)<br>3 |  |  |
| Dysgeusia<br>subjects affected / exposed<br>occurrences (all)               | 1 / 14 (7.14%)<br>1  |  |  |
| Headache<br>subjects affected / exposed<br>occurrences (all)                | 1 / 14 (7.14%)<br>1  |  |  |
| Neuropathy peripheral<br>subjects affected / exposed<br>occurrences (all)   | 0 / 14 (0.00%)<br>0  |  |  |
| Nystagmus<br>subjects affected / exposed<br>occurrences (all)               | 1 / 14 (7.14%)<br>1  |  |  |
| Presyncope<br>subjects affected / exposed<br>occurrences (all)              | 0 / 14 (0.00%)<br>0  |  |  |
| Blood and lymphatic system disorders                                        |                      |  |  |

|                             |                |  |  |
|-----------------------------|----------------|--|--|
| Anaemia                     |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Blood loss anaemia          |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Leukocytosis                |                |  |  |
| subjects affected / exposed | 1 / 14 (7.14%) |  |  |
| occurrences (all)           | 1              |  |  |
| Leukopenia                  |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Lymph node pain             |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Ear and labyrinth disorders |                |  |  |
| Ear congestion              |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Tinnitus                    |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Vertigo                     |                |  |  |
| subjects affected / exposed | 1 / 14 (7.14%) |  |  |
| occurrences (all)           | 2              |  |  |
| Eye disorders               |                |  |  |
| Diplopia                    |                |  |  |
| subjects affected / exposed | 1 / 14 (7.14%) |  |  |
| occurrences (all)           | 1              |  |  |
| Eyelid ptosis               |                |  |  |
| subjects affected / exposed | 1 / 14 (7.14%) |  |  |
| occurrences (all)           | 1              |  |  |
| Periorbital oedema          |                |  |  |
| subjects affected / exposed | 1 / 14 (7.14%) |  |  |
| occurrences (all)           | 1              |  |  |
| Vision blurred              |                |  |  |

|                             |                 |  |  |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 1 / 14 (7.14%)  |  |  |
| occurrences (all)           | 2               |  |  |
| Gastrointestinal disorders  |                 |  |  |
| Abdominal discomfort        |                 |  |  |
| subjects affected / exposed | 0 / 14 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Abdominal distension        |                 |  |  |
| subjects affected / exposed | 1 / 14 (7.14%)  |  |  |
| occurrences (all)           | 1               |  |  |
| Abdominal pain              |                 |  |  |
| subjects affected / exposed | 2 / 14 (14.29%) |  |  |
| occurrences (all)           | 2               |  |  |
| Colitis                     |                 |  |  |
| subjects affected / exposed | 0 / 14 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Constipation                |                 |  |  |
| subjects affected / exposed | 1 / 14 (7.14%)  |  |  |
| occurrences (all)           | 1               |  |  |
| Dental caries               |                 |  |  |
| subjects affected / exposed | 1 / 14 (7.14%)  |  |  |
| occurrences (all)           | 1               |  |  |
| Diarrhoea                   |                 |  |  |
| subjects affected / exposed | 2 / 14 (14.29%) |  |  |
| occurrences (all)           | 2               |  |  |
| Dyspepsia                   |                 |  |  |
| subjects affected / exposed | 0 / 14 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Dysphagia                   |                 |  |  |
| subjects affected / exposed | 0 / 14 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Flatulence                  |                 |  |  |
| subjects affected / exposed | 1 / 14 (7.14%)  |  |  |
| occurrences (all)           | 1               |  |  |
| Hiatus hernia               |                 |  |  |
| subjects affected / exposed | 0 / 14 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |

|                                                                        |                      |  |  |
|------------------------------------------------------------------------|----------------------|--|--|
| Hypoaesthesia oral<br>subjects affected / exposed<br>occurrences (all) | 0 / 14 (0.00%)<br>0  |  |  |
| Inguinal hernia<br>subjects affected / exposed<br>occurrences (all)    | 0 / 14 (0.00%)<br>0  |  |  |
| Nausea<br>subjects affected / exposed<br>occurrences (all)             | 3 / 14 (21.43%)<br>4 |  |  |
| Rectal tenesmus<br>subjects affected / exposed<br>occurrences (all)    | 0 / 14 (0.00%)<br>0  |  |  |
| Toothache<br>subjects affected / exposed<br>occurrences (all)          | 0 / 14 (0.00%)<br>0  |  |  |
| Vomiting<br>subjects affected / exposed<br>occurrences (all)           | 0 / 14 (0.00%)<br>0  |  |  |
| Skin and subcutaneous tissue disorders                                 |                      |  |  |
| Alopecia<br>subjects affected / exposed<br>occurrences (all)           | 0 / 14 (0.00%)<br>0  |  |  |
| Dry skin<br>subjects affected / exposed<br>occurrences (all)           | 0 / 14 (0.00%)<br>0  |  |  |
| Ecchymosis<br>subjects affected / exposed<br>occurrences (all)         | 0 / 14 (0.00%)<br>0  |  |  |
| Erythema<br>subjects affected / exposed<br>occurrences (all)           | 0 / 14 (0.00%)<br>0  |  |  |
| Hyperhidrosis<br>subjects affected / exposed<br>occurrences (all)      | 2 / 14 (14.29%)<br>4 |  |  |
| Night sweats                                                           |                      |  |  |

|                             |                |  |  |
|-----------------------------|----------------|--|--|
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Pruritus                    |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Rash                        |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Rash papular                |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Skin discolouration         |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Skin hyperpigmentation      |                |  |  |
| subjects affected / exposed | 1 / 14 (7.14%) |  |  |
| occurrences (all)           | 1              |  |  |
| Skin reaction               |                |  |  |
| subjects affected / exposed | 1 / 14 (7.14%) |  |  |
| occurrences (all)           | 1              |  |  |
| Skin swelling               |                |  |  |
| subjects affected / exposed | 1 / 14 (7.14%) |  |  |
| occurrences (all)           | 1              |  |  |
| Skin texture abnormal       |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Renal and urinary disorders |                |  |  |
| Dysuria                     |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Hydronephrosis              |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Urinary hesitation          |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |

|                                                 |                |  |  |
|-------------------------------------------------|----------------|--|--|
| Endocrine disorders                             |                |  |  |
| Hyperthyroidism                                 |                |  |  |
| subjects affected / exposed                     | 0 / 14 (0.00%) |  |  |
| occurrences (all)                               | 0              |  |  |
| Hypothyroidism                                  |                |  |  |
| subjects affected / exposed                     | 0 / 14 (0.00%) |  |  |
| occurrences (all)                               | 0              |  |  |
| Musculoskeletal and connective tissue disorders |                |  |  |
| Arthralgia                                      |                |  |  |
| subjects affected / exposed                     | 0 / 14 (0.00%) |  |  |
| occurrences (all)                               | 0              |  |  |
| Back pain                                       |                |  |  |
| subjects affected / exposed                     | 1 / 14 (7.14%) |  |  |
| occurrences (all)                               | 1              |  |  |
| Bone pain                                       |                |  |  |
| subjects affected / exposed                     | 0 / 14 (0.00%) |  |  |
| occurrences (all)                               | 0              |  |  |
| Flank pain                                      |                |  |  |
| subjects affected / exposed                     | 0 / 14 (0.00%) |  |  |
| occurrences (all)                               | 0              |  |  |
| Gouty arthritis                                 |                |  |  |
| subjects affected / exposed                     | 0 / 14 (0.00%) |  |  |
| occurrences (all)                               | 0              |  |  |
| Groin pain                                      |                |  |  |
| subjects affected / exposed                     | 0 / 14 (0.00%) |  |  |
| occurrences (all)                               | 0              |  |  |
| Muscle spasms                                   |                |  |  |
| subjects affected / exposed                     | 1 / 14 (7.14%) |  |  |
| occurrences (all)                               | 1              |  |  |
| Musculoskeletal chest pain                      |                |  |  |
| subjects affected / exposed                     | 0 / 14 (0.00%) |  |  |
| occurrences (all)                               | 0              |  |  |
| Musculoskeletal pain                            |                |  |  |
| subjects affected / exposed                     | 0 / 14 (0.00%) |  |  |
| occurrences (all)                               | 0              |  |  |
| Myalgia                                         |                |  |  |

|                             |                 |  |  |
|-----------------------------|-----------------|--|--|
| subjects affected / exposed | 2 / 14 (14.29%) |  |  |
| occurrences (all)           | 3               |  |  |
| Pain in extremity           |                 |  |  |
| subjects affected / exposed | 0 / 14 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Plantar fasciitis           |                 |  |  |
| subjects affected / exposed | 0 / 14 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Infections and infestations |                 |  |  |
| Candida infection           |                 |  |  |
| subjects affected / exposed | 0 / 14 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Cellulitis                  |                 |  |  |
| subjects affected / exposed | 0 / 14 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Conjunctivitis              |                 |  |  |
| subjects affected / exposed | 0 / 14 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Diverticulitis              |                 |  |  |
| subjects affected / exposed | 0 / 14 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Helicobacter duodenitis     |                 |  |  |
| subjects affected / exposed | 0 / 14 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Herpes virus infection      |                 |  |  |
| subjects affected / exposed | 1 / 14 (7.14%)  |  |  |
| occurrences (all)           | 1               |  |  |
| Influenza                   |                 |  |  |
| subjects affected / exposed | 1 / 14 (7.14%)  |  |  |
| occurrences (all)           | 1               |  |  |
| Nasopharyngitis             |                 |  |  |
| subjects affected / exposed | 0 / 14 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |
| Oesophagitis bacterial      |                 |  |  |
| subjects affected / exposed | 0 / 14 (0.00%)  |  |  |
| occurrences (all)           | 0               |  |  |

|                                    |                 |  |  |
|------------------------------------|-----------------|--|--|
| Oral herpes                        |                 |  |  |
| subjects affected / exposed        | 1 / 14 (7.14%)  |  |  |
| occurrences (all)                  | 1               |  |  |
| Rhinovirus infection               |                 |  |  |
| subjects affected / exposed        | 0 / 14 (0.00%)  |  |  |
| occurrences (all)                  | 0               |  |  |
| Sinusitis                          |                 |  |  |
| subjects affected / exposed        | 0 / 14 (0.00%)  |  |  |
| occurrences (all)                  | 0               |  |  |
| Tooth infection                    |                 |  |  |
| subjects affected / exposed        | 1 / 14 (7.14%)  |  |  |
| occurrences (all)                  | 1               |  |  |
| Upper respiratory tract infection  |                 |  |  |
| subjects affected / exposed        | 1 / 14 (7.14%)  |  |  |
| occurrences (all)                  | 1               |  |  |
| Urinary tract infection            |                 |  |  |
| subjects affected / exposed        | 1 / 14 (7.14%)  |  |  |
| occurrences (all)                  | 1               |  |  |
| Metabolism and nutrition disorders |                 |  |  |
| Decreased appetite                 |                 |  |  |
| subjects affected / exposed        | 0 / 14 (0.00%)  |  |  |
| occurrences (all)                  | 0               |  |  |
| Hyperglycaemia                     |                 |  |  |
| subjects affected / exposed        | 1 / 14 (7.14%)  |  |  |
| occurrences (all)                  | 2               |  |  |
| Hyperkalaemia                      |                 |  |  |
| subjects affected / exposed        | 2 / 14 (14.29%) |  |  |
| occurrences (all)                  | 2               |  |  |
| Hyperlipidaemia                    |                 |  |  |
| subjects affected / exposed        | 1 / 14 (7.14%)  |  |  |
| occurrences (all)                  | 1               |  |  |
| Hypernatraemia                     |                 |  |  |
| subjects affected / exposed        | 0 / 14 (0.00%)  |  |  |
| occurrences (all)                  | 0               |  |  |
| Hyperuricaemia                     |                 |  |  |

|                             |                |  |  |
|-----------------------------|----------------|--|--|
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Hypoalbuminaemia            |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Hypocalcaemia               |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Hypokalaemia                |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |
| Hyponatraemia               |                |  |  |
| subjects affected / exposed | 0 / 14 (0.00%) |  |  |
| occurrences (all)           | 0              |  |  |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date             | Amendment                                                                                                                                                                                                                                                                                                                                                                                                |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 05 November 2015 | AM1 - This amendment added a treatment arm to Part 2 Patient Expansion to examine the sequential addition of anti-PD1 antibody pembrolizumab to intratumoral G100.                                                                                                                                                                                                                                       |
| 05 January 2017  | AM3 - Added Part 3 G100 20µg Dose Expansion arm to allow for up to 25 participants at the 20µg dose using the same tumor size entrance criteria as the other non-Large Tumor arms.                                                                                                                                                                                                                       |
| 31 July 2018     | AM4 - Added Part 4, a new dose escalation and expansion arm to examine G100 20µg in combination with pembrolizumab in relapsed or refractory follicular lymphoma without radiation therapy in single and multiple tumor lesions. Added Part 5, a new dose escalation and expansion to examine the safety and preliminary clinical efficacy of G100 in combination with rituximab in follicular lymphoma. |
| 31 August 2018   | AM4A - Revised the Inclusion criteria for Part 4 to only include participants with relapsed or refractory disease after ≥3 prior therapies. Part 5 was revised to limit the intratumoral G100 treatment to a single tumor mass during Patient Expansion.                                                                                                                                                 |
| 15 November 2018 | AM4B - An exploratory objective of evaluating Pharmacokinetics and Pharmacodynamic properties of G100 and appropriate sample collection were added. Dose limiting toxicity criteria for Parts 4 and 5 were added.                                                                                                                                                                                        |

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

| Date         | Interruption                                                        | Restart date |
|--------------|---------------------------------------------------------------------|--------------|
| 11 June 2019 | The trial was terminated (Halted Prematurely) for business reasons. | -            |

Notes:

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Part 5, G100 plus Rituximab, Dose Escalation: 12 to 24 participants were planned; no participant was enrolled or dosed. The trial was terminated (Halted Prematurely) for business reasons.

Notes: